WO2006122797A2 - Anti-gm-csf antibodies and uses therefor - Google Patents

Anti-gm-csf antibodies and uses therefor Download PDF

Info

Publication number
WO2006122797A2
WO2006122797A2 PCT/EP2006/004696 EP2006004696W WO2006122797A2 WO 2006122797 A2 WO2006122797 A2 WO 2006122797A2 EP 2006004696 W EP2006004696 W EP 2006004696W WO 2006122797 A2 WO2006122797 A2 WO 2006122797A2
Authority
WO
WIPO (PCT)
Prior art keywords
human
csf
antibody
isolated
seq
Prior art date
Application number
PCT/EP2006/004696
Other languages
French (fr)
Other versions
WO2006122797A3 (en
WO2006122797B1 (en
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK06742970.4T priority Critical patent/DK1888643T3/en
Priority to EP06742970.4A priority patent/EP1888643B1/en
Priority to KR1020077029189A priority patent/KR101308087B1/en
Priority to JP2008511635A priority patent/JP5295759B2/en
Priority to AU2006249062A priority patent/AU2006249062B2/en
Priority to SI200631880T priority patent/SI1888643T1/en
Priority to PL06742970T priority patent/PL1888643T3/en
Priority to MEP-2015-5A priority patent/ME02059B/en
Priority to CN2006800249817A priority patent/CN101218255B/en
Application filed by Morphosys Ag filed Critical Morphosys Ag
Priority to NZ564027A priority patent/NZ564027A/en
Priority to EP19180152.1A priority patent/EP3620171B1/en
Priority to CA2608498A priority patent/CA2608498C/en
Priority to US11/914,599 priority patent/US7867495B2/en
Priority to RS20150018A priority patent/RS53743B1/en
Priority to BRPI0610796A priority patent/BRPI0610796B8/en
Priority to ES06742970.4T priority patent/ES2527428T3/en
Publication of WO2006122797A2 publication Critical patent/WO2006122797A2/en
Publication of WO2006122797A3 publication Critical patent/WO2006122797A3/en
Publication of WO2006122797B1 publication Critical patent/WO2006122797B1/en
Priority to IL187375A priority patent/IL187375A/en
Priority to NO20076437A priority patent/NO344992B1/en
Priority to HK08109862.8A priority patent/HK1114620A1/en
Priority to US12/923,363 priority patent/US9751939B2/en
Priority to HRP20150023TT priority patent/HRP20150023T1/en
Priority to US15/386,152 priority patent/US10377820B2/en
Priority to US16/442,779 priority patent/US11028165B2/en
Priority to US17/314,198 priority patent/US20210347879A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • Granulocyte-macrophage colony stimulating factor was originally identified as a hemopoietic growth factor. It is produced by a number of cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells (Metcalf et al., 1986; Clark and Kamen, 1987; Hart et al, 1988; Metcalf et al., 1986). In addition to having a function of growth stimulation and differentiation on hemopoietic precursor cells, GM-CSF also was discovered as having a variety of effects on cells of the immune system expressing the GM-CSF receptor (for review see: Hamilton, 2002; de Groot et al., 1998).
  • Mature GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The variable degree of glycosylation results in a molecular weight range between 14kDa and 35kDa.
  • Non-glycosylated and glycosylated GM-CSF show similar activity in vitro (Cebon et al., 1990).
  • the crystallographic analysis of GM-CSF revealed a barrel- shaped structure composed of four short alpha helices (Diederichs et al., 1991). The overall folding is similar to other growth factors like growth hormone, interleukin-2 and in- terleukin-4.
  • GM-CSF exerts its biological activity by binding to its receptor (Kastelein and Sha- nafelt, 1993; Sisson and Dinarello, 1988).
  • the most important sites of GM-CSF receptor (GM-CSF-R) expression are on the cell surface of myeloid cells and endothelial cells, whereas lymphocytes are GM-CSF-R negative.
  • the native receptor is composed of at least two subunits, alpha and beta. The alpha subunit imparts ligand specificity and binds GM-CSF with nanomolar affinity (Gearing et al., 1989; Gasson et al., 1986).
  • the beta subunit is also part of the interleukin-3 and interleukin-5 receptor complexes and, in association with the GM-CSF receptor alpha subunit and GM-CSF, leads to the formation of a complex with picomolar binding affinity (Hayashida et al., 1990).
  • the binding domains on GM-CSF for the receptor have been mapped: GM-CSF interacts with the beta subunit of its receptor via a very restricted region in the first alpha helix of GM-CSF (Shanafelt et al., 1991b; Shanafelt et al., 1991a; Lopez et al., 1991).
  • Binding to the alpha subunit could be mapped to the third alpha helix, helix C, the initial residues of the loop joining helices C and D, and to the carboxyterminal tail of GM-CSF (Brown et al., 1994).
  • GM-CSF trimeric receptor complex leads to the activation of com- plex signaling cascades involving molecules of the JAK/STAT families, She, Ras, Raf, the MAP kinases, phosphatidylinositol-3 -kinase and NFkB, finally leading to transcription of c-myc, c-fos and c-jun.
  • Activation is mainly induced by the beta subunit of the receptor (Hayashida et al., 1990; Kitamura et al., 1991; Sato et al., 1993).
  • the shared beta subunit is also responsible for the overlapping functions exerted by IL-3, IL-5 and GM- CSF (for review see: de Groot et al., 1998).
  • GM-CSF functions especially as a proinflammatory cytokine. Macrophages and monocytes as well as neutrophils and eosinophils become activated by GM-CSF, resulting in the release of other cytokines and chemokines, matrix degrading proteases, increased HLA expression and increased expression of cell adhesion molecules or receptors for CC-chemokines.
  • GM-CSF exerts its activity in synergy with other inflammatory stimulating factors like other cytokines or LPS, e.g. neutrophils treated with GM-CSF in combination with e.g. LPS will show increased oxidative burst (Kaufman et al., 1989; Rapoport et al., 1992).
  • GM-CSF as target for anti-inflammatory therapy:
  • GM-CSF can be con- sidered as a target for anti-inflammatory therapy.
  • Chronic and acute inflammatory diseases like rheumatoid arthritis (RA), multiple sclerosis (MS), Crohn's disease, psoriasis, asthma, atopic dermatitis or shock may well benefit from the blocking of GM-CSF activity and subsequent reduction of harmful activities of GM-CSF responsive cells (Hamilton, 1993; Zhang et al., 1998; Hamilton, 2002).
  • GM-CSF as well as its receptor, are present in the synovial joint of arthritis patients (Alvaro-Gracia et al., 1991; Xu et al., 1989; Haworth et al., 1991). Additionally, GM-CSF was shown to cause flares of rheumatoid arthritis in patients treated with GM-CSF for neutropenia in Felty's syndrome (Hazenberg et al., 1989) or after chemotherapy (de Vries et al., 1991).
  • Blocking GM-CSF is expected to inhibit or reduce: a) the activation and number of mature monocytes, macrophages, and neutro- phils. Especially neutrophils and macrophages are abundant in synovial fluid and membrane. The macrophage number in the synovium has been shown to correlate with the degree of erosion in RA joints (Mulherin et al., 1996; Burmester et al., 1997). Macrophages are the source of a variety of other proinflammatory cytokines and matrix degrading proteases. Production of H 2 O 2 by neutrophils is part of the destructive processes taking place in the arthritic joints (Babior, 2000).
  • DCs myeloid dendritic cells
  • synovial DCs synovial DCs
  • GM-CSF upregulates and maintains HLA class II expression on DCs and RA synoviocytes (Alvaro-Gracia JM et al., 1991).
  • DCs are instructed within the joint to acquire functions associated with the selective activation of inflammatory T- cells.
  • Specific HLA-DR alleles have been linked to susceptibility to RA, and activation of T-cells via antigen presentation of DCs may play a crucial role in this type of immune disease (Santiago-Schwarz et al., 2001).
  • GM-CSF-/- mice In multiple sclerosis, elevated levels of GM-CSF correlate with the active phase of MS (Carried et al., 1998; McQualter et al., 2001) and GM-CSF-/- mice fail to develop disease in the model system for MS, experimental encephalomyelitis, EAE (McQualter et al., 2001).
  • GM-CSF GM-CSF
  • eosinophils are elevated, on which GM-CSF in synergy with interleukin-5 acts in three ways: i) it stimulates the differentiation from progenitor cells into eosinophils, ii) it stimulates their functional activation, and iii) it prolongs the survival of eosinophils in the lung (Broide et al., 1992; Yamashita et al., 2002).
  • GM-CSF neutralizing antibodies was further shown in a model for murine asthma where the administration of such antibodies led to significant reduction of airway hyperresponsiveness and airway inflammation (Yamashita et al., 2002).
  • GM-CSF granulocyte/macrophage colony-stimulating factor
  • GM-CSF does not seem to be essential for the maintenance of normal levels of the major types of mature hematopoietic cells and their precursors in blood, marrow, and spleen. However, they implicate GM-CSF as being essential for normal vascular development, pulmonary physiology, and for resistance to local infection (Stanley et al., 1994; Dranoff et al., 1994; Plenz et al., 2003; Shibata et al., 2001). Recently, a strong association of auto-antibodies to GM-CSF with PAP has additionally implicated GM-CSF signaling abnormalities in the pathogenesis of PAP in humans.
  • GM-CSF has a critical role in regulation of surfactant homeostasis and alveolar macrophage innate immune functions in the lung (Bonfield et al., 2002; Trapnell and Whitsett, 2002; Uchida et al., 2004; Kitamura et al., 1999).
  • the compound E21R a modified form of GM-CSF that antagonizes the function of GM-CSF, had been evaluated in a phase I safety trial and was found to have a good safety profile in cancer patients (Olver et al., 2002).
  • EP 0499161 Al describes an antibody gener- ated by immunization of mice with oligopeptides, the sequence of which is derived from a GM-CSF.
  • the application discloses a method of alleviating in a mammal in need thereof an undesirable effect of GM-CSF, which comprises administering to said mammal a GM-CSF-inhibiting amount of an immunoglobulin.
  • that antibody is a murine antibody, rendering it unsuitable for human administration.
  • WO 03/068920 discloses an inhibitory chimeric mouse/human IgGl antibody.
  • Antibodies that contain non-human sequences are likely to elicit an immune response in the human patient and are not appropriate for the therapeutic administration. For instance, in diseases where long-term treatment is required (e.g. chronic inflammatory diseases like rheumatoid arthritis, asthma and multiple sclerosis), continued administra- tion of a non-human therapeutic agent increases the likelihood of a severe inflammatory reaction and the production of human antibodies that may neutralize the therapeutic agent.
  • diseases where long-term treatment is required e.g. chronic inflammatory diseases like rheumatoid arthritis, asthma and multiple sclerosis
  • continued administra- tion of a non-human therapeutic agent increases the likelihood of a severe inflammatory reaction and the production of human antibodies that may neutralize the therapeutic agent.
  • anti-GM-CSF antibody therapy there is a high need for human anti-GM-CSF antibodies with high affinity that effectively block the GM-CSF/GM-CSF receptor interaction.
  • the present invention satisfies these and other needs by providing fully highly efficacious anti-GM-CSF antibodies, which are described below.
  • the invention provides an antigen-binding region that is specific for human GM-CSF, where the isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 ⁇ g/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2xlO 5 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of the human GM-CSF recep- tor alpha chain expressed on the CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x10 5 CHO-GMRa#l l cells, and (b) the concentration of the isolated human or humanized antibody or functional fragment thereof is about 5 ⁇ g/ml; and (ii) to neutralize 0.25 ng
  • TF-I proliferation assay is defined as the assay essentially as described in Example 5B.
  • the skilled worker can obtain CHO-Kl cells expressing human GM-CSF receptor alpha chain at a concentration similar to that which is expressed on about 2x10 5 CH0-GMRa#l 1 cells by following the teachings provided herein.
  • the invention additionally provides an isolated human or humanized antibody or functional antibody fragment that contains an antigen-binding region as disclosed herein.
  • Such an antibody or functional fragment thereof may contain an antigen-binding region that contains an H-CDR3 region depicted in SEQ ID NO: 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; the antigen-binding region may further include an H-CDR2 re- gion depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; and the antigen-binding region also may contain an H-CDRl region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
  • Such an antibody or functional fragment thereof may contain an antigen-binding region that contains a variable heavy chain depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
  • a GM-CSF-specific antibody of the invention may contain an antigen-binding re-gion that contains an L-CDR3 region depicted in SEQ ID NO: 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; the antigen-binding region may further include an L-CDR2 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and the antigen-binding region also may contain an L-CDRl region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
  • Such an antibody or functional fragment thereof may contain an anti
  • the invention includes anti-GM-CSF antibodies having a heavy chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
  • anti-GM-CSF antibodies having a light chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
  • An antibody of the invention may be an IgG (e.g., IgGi), while an antibody fragment may be a Fab or scFv, for example.
  • An inventive antibody fragment accordingly, may be, or may contain, an antigen-binding region that behaves in one or more ways as described herein.
  • the invention also is related to isolated nucleic acid sequences, each of which can encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for GM-CSF.
  • a nucleic acid sequence may encode a variable heavy chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, or a nu- cleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48.
  • the nucleic acid might encode a variable light chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57, or a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57.
  • the nucleic acid sequence might encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for human GM- CSF, where the antibody or functional fragment thereof is able (i) to block interaction of 0.5 ⁇ g/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on 2x10 s CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM-CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on 2x10 5 CHO-GMRa#l 1 cells and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5 ⁇ g/ml, and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC 50 value than the reference antibody BVD2-21C11 and/or reference antibody MAB215.
  • Nucleic acids of the invention are suitable for recombinant production.
  • the invention also relates to vectors and host cells containing a nucleic acid sequence of the invention.
  • host cells might be bacterial or eukaryotic cells.
  • compositions of the invention may be used for therapeutic or prophylactic applications.
  • the invention therefore, includes a pharmaceutical composition containing an inventive antibody (or functional antibody fragment) and a pharmaceutically acceptable carrier or excipient therefor.
  • the invention provides a method for treating a disorder or condition associated with the undesired presence of GM-CSF or GM-CSF expressing cells.
  • Such method contains the steps of administering to a subject in need thereof an effective amount of the pharmaceutical composition that contains an inventive antibody as described or contemplated herein.
  • a disorder or condition might be an inflammatory disease, such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis and shock.
  • Human or humanized antibodies (and functional fragments thereof) of the present invention may be cross-reactive with rat and/or rhesus (macaca) GM-CSF, as determined by solution equilibrium titration (SET), and/or TFl proliferation assay.
  • SET solution equilibrium titration
  • Figure Ia provides nucleic acid sequences of various novel antibody variable heavy chain regions.
  • Figure Ib provides amino acid sequences of various novel antibody variable heavy chain regions.
  • CDR regions HCDRl, HCDR2 and HCDR3 are designated from N- to C- terminus in boldface.
  • Figure 2a provides nucleic acid sequences of various novel antibody variable light chain regions.
  • FIG. 2b provides amino acid sequences of various novel antibody variable light chain regions.
  • CDR regions LCDRl, LCDR2 and LCDR3 are designated from N- to C- terminus in boldface.
  • Figure 3 provides amino acid sequences of variable heavy chain regions of consensus-based HuC AL ® antibody master gene sequences.
  • CDR regions HCDRl, HCDR2 and HCDR3 are designated from N- to C-terminus in boldface (SEQ ID NO: 41).
  • Figure 4 provides amino acid sequences of variable light chain regions of consen : sus-based HuCAL ® antibody master gene sequences.
  • CDR regions LCDRl , LCDR2 and LCDR3 are designated from N- to C-terminus in boldface (SEQ ID NO: 42).
  • Figure 5 provides an example of a DNA sequence of pMORPH ® X9_MOR03929_FH expression vector (SEQ ID NO: 43).
  • Figure 6 provides expression level of GM-CSF receptor alpha, as determined by
  • CHO- GMRa#l 1 solid line
  • CHO-Kl dotted line
  • the x-axis represents the relative fluorescence value (RFL), measured in FL2 channel; the y-axis represents cell count.
  • the present invention is based on the discovery of novel antibodies that are specific to or have a high affinity for GM-CSF and possess one or more other novel properties.
  • an antibody of the invention can deliver a therapeutic benefit to a subject.
  • the antibodies of the invention which may be human or humanized, can be used in many contexts, which are more fully described herein.
  • a "human” antibody or functional human antibody fragment is hereby defined as one that is not chimeric (e.g., not “humanized”) and not from (either in whole or in part) a non-human species.
  • a human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody.
  • a "synthetic human antibody” is defined herein as an antibody having a sequence derived, in whole or in part, in silico from synthetic sequences that are based on the analysis of known human antibody sequences. In silico design of a human antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom.
  • Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (i.e., such library being based on antibodies taken from a human natural source).
  • a “humanized antibody” or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frame- works of the variable domain are of human origin and the constant domain (if any) is of human origin.
  • a non-human source e.g., a transgenic mouse which bears a heterologous immune system
  • chimeric wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin
  • CDR-grafted wherein the CDRs of the variable domain are from a non-human origin, while one or more frame
  • an antibody “binds specifically to,” is “specific to/for” or “specifically recognizes” an antigen (here, GM-CSF) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property.
  • antigen here, GM-CSF
  • “specific binding” is referring to the ability of the antibody to dis- criminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-,ECL-, IRMA-tests and peptide scans.
  • a standard ELISA assay can be carried out.
  • the scoring may be carried out by standard color development ⁇ e.g. secondary antibody with horseradish peroxide and tet- ramethyl benzidine with hydrogenperoxide).
  • the reaction in certain wells is scored by the optical density, for example, at 450 nm.
  • determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like.
  • binding also may refer to the ability of an antibody to discriminate between the target antigen and one or more closely related antigen(s), which are used as reference points, e.g. between GM-CSF and IL3, IL5, IL-4, IL13 or M-CSF.
  • specifically binding may relate to the ability of an antibody to discriminate between different parts of its target antigen, e.g. different domains or regions of GM-CSF, or between one or more key amino acid residues or stretches of amino acid residues of GM- CSF.
  • an “immunoglobulin” hereby is defined as a protein be- longing to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof.
  • a "functional fragment" of an antibody/immunoglobulin hereby is defined as a fragment of an anti- body/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region.
  • an "antigen-binding region" of an antibody typically is found in one or more hypervariable region(s) of an antibody, i.e., the CDR-I, -2, and/or -3 regions; however, the variable "framework" regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs.
  • the "antigen-binding region” comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320).
  • a preferred class of immunoglobulins for use in the present invention is IgG.
  • “Functional fragments” of the invention include the domain of a F(ab') 2 fragment, a Fab fragment, scFv or constructs comprising single immunoglobulin variable domains or single domain antibody polypeptides, e.g. single heavy chain variable domains or single light chain variable domains.
  • the F(ab') 2 or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the CH I and CL domains.
  • An antibody of the invention may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed in silico and encoded by nucleic acids that are synthetically created.
  • silico design of an antibody sequence is achieved, for example, by analyzing a database of human sequences and devising a polypeptide sequence utilizing the data obtained therefrom.
  • Methods for designing and obtaining in silico-c ⁇ eated sequences are described, for example, in Knappik et ⁇ l., J. MoI. Biol. (2000) 296:57; Krebs et ⁇ l., J. Immunol. Methods. (2001) 254:67; and U.S. Patent No. 6,300,064 issued to Knappik et ⁇ l., which hereby are incorporated by reference in their entirety.
  • MOR03684 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 1 (DNA)/SEQ ID NO: 1 1 (protein) and a variable light region corresponding to SEQ ID NO: 21 (DNA)/SEQ ID NO: 31 (protein).
  • MOR04251 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 2 (DNA)/SEQ ID NO: 12 (protein) and a variable light region corresponding to SEQ ID NO: 22 (DNA)/SEQ ID NO: 32 (protein).
  • MOR03929 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 3 (DNA)/SEQ ID NO: 13 (protein) and a variable light region corresponding to SEQ ID NO: 23 (DNA)/SEQ ID NO: 33 (protein).
  • MOR04252 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 4 (DNA)/SEQ ID NO: 14 (protein) and a variable light region corresponding to SEQ ID NO: 24 (DNA)/SEQ ID NO: 34 (protein).
  • MOR04287 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 5 (DNA)/SEQ ID NO: 15 (protein) and a variable light region corresponding to SEQ ID NO: 25 (DNA)/SEQ ID NO: 35 (protein).
  • MOR04290 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 6 (DNA)/SEQ ID NO: 16 (protein) and a variable light region corresponding to SEQ ID NO: 26 (DNA)/SEQ ID NO: 36 (protein).
  • MOR04302 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 7 (DNA)/SEQ ID NO: 17 (protein) and a variable light region corresponding to SEQ ID NO: 27 (DNA)/SEQ ID NO: 37 (protein).
  • MOR04350 represents an antibody having a variable heavy region cor- responding to SEQ ID NO: 8 (DNA)/SEQ ID NO: 18 (protein) and a variable light region corresponding to SEQ ID NO: 28 (DNA)/SEQ ID NO: 38 (protein).
  • MOR04354 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 9 (DNA)/SEQ ID NO: 19 (protein) and a variable light region corresponding to SEQ ID NO: 29 (DNA)/SEQ ID NO: 39 (protein).
  • MOR04357 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 10 or 48 (DNA)/SEQ ID NO: 20 (protein) and a variable light region corresponding to SEQ ID NO: 30 or 57 (DNA)/SEQ ID NO: 40 (protein).
  • MOR03682 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 44 (DNA)/SEQ ID NO: 49 (protein) and a variable light region corresponding to SEQ ID NO: 53 (DNA)/SEQ ID NO: 58 (protein).
  • MOR04283 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 45 (DNA)/SEQ ID NO: 50 (protein) and a variable light region corresponding to SEQ ID NO: 54 (DNA)/SEQ ID NO: 59 (protein).
  • MOR04297 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 46 (DNA)/SEQ ID NO: 51 (protein) and a variable light region corresponding to SEQ ID NO: 55 (DNA)/SEQ ID NO: 60 (protein).
  • MOR04342 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 47 (DNA)/SEQ ID NO: 52 (protein) and a variable light region corresponding to SEQ ID NO: 56 (DNA)/SEQ ID NO: 61 (protein).
  • the invention provides antibodies having an antigen-binding region that can bind specifically to or has a high affinity for GM-CSF.
  • An antibody is said to have a "high affinity" for an antigen if the affinity measurement is at least 100 nM
  • An inventive antibody or antigen-binding region preferably can bind to GM-CSF with an affinity of about less than 100 nM, more preferably less than about 60 nM, and still more preferably less than about 30 nM. Further preferred are antibodies that bind to GM-CSF with an affinity of less than about 10 nM, and more preferably less than about 3 nM.
  • the affinity of an antibody of the invention against GM-CSF may be about 10.0 nM or 1 pM (monovalent affinity of Fab fragment).
  • Table 1 provides a summary of affinities of representative antibodies of the invention, as determined by surface plasmon resonance (Biacore) and Solution Equilibrium Titration (SET) analysis:
  • 04290, 04302, 04350 and 04354 was measured by surface plasmon resonance (Biacore) on immobilized recombinant GM-CSF.
  • the Fab format of MOR03684, 04251, 03929, 04252, 04357, 04290, 04302, 04350 and 04354 exhibit a monovalent affinity range between about 6420 and 7 pM.
  • the Fab format was also used for the determination of the affinities by solution equilibrium titration (SET).
  • SET solution equilibrium titration
  • the right column of Table 1 denotes the binding strength of between about 16000 and 0.4 pM of the MORs in this method.
  • An antibody of the invention preferably is species cross-reactive with humans and at least one other species, which may be a rodent species or a non-human primate.
  • the non- human primate can be rhesus.
  • the rodent species can be rat.
  • An antibody that is cross reactive with at least one rodent species, for example, can provide greater flexibility and benefits over known anti-GM-CSF antibodies, for purposes of conducting in vivo studies in multiple species with the same antibody.
  • an antibody of the invention not only is able to bind to GM-CSF, but also is able to block the interaction of human GM-CSF with the alpha chain of human GM-CSF receptor expressed on CHO-Kl cells by at least 25%, preferably by at least 50%, more preferably by at least 60%, more preferably by at least 70%, preferably by at least 85% and most preferably by at least 100%.
  • an antibody of the invention is able to block interaction of 0.5 ⁇ g/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x10 5 CHO-Kl cells by at least 50% under the following conditions: the concentration of the human GM-CSF receptor alpha chain expressed on the CHO-Kl cells is similar to the concentration of human GM- CSF receptor alpha chain expressed on about 2x10 5 CHO-GMRa#l 1 cells, and the concentration of the inventive antibody is about 5 ⁇ g/ml.
  • the skilled worker can obtain CHO-Kl cells expressing human GM-
  • CSF receptor alpha at a concentration similar to that which is expressed on about 2x10 5 CHO-GMRa#l l cells by, e.g., by transfecting a population of CHO-Kl cells with a suitable expression vector encoding GM-CSF receptor alpha to generate different stable cell lines expressing defined levels GM-CSF receptor alpha; then, the stable cell lines are analyzed in FACS analysis to determine GM-CSF receptor alpha expression levels according to the protocol essentially as described in Example 3C; a cell line that expresses human GM-CSF receptor alpha at a concentration similar to that which is expressed on about 2x10 5 CHO-GMRa#l l cells is identified by comparing the median fluorescence value (MFL) of such transfected cells to the MFL value set forth in Example 3C.
  • MFL median fluorescence value
  • a cell line is defined as expressing GM-CSF receptor alpha at a concentration "similar” to that which is expressed on about 2x10 s CHO-GMRa#l l cells" if the MFL value of the transfected cell line does not deviate by more than a two-fold factor from the MFL value for the CHO-GMRa#l 1 cell as set forth in Example 3C.
  • an antibody of the invention is able to neutralize human GM-CSF in a TF-I proliferation assay with a lower IC 50 value than the reference antibody BVD2- 21Cl 1 and/or MAB215, preferably an at least five-fold lower IC 50 value, more preferably with an at least 10-fold lower IC 50 value than the reference antibody BVD2-21C1 1 and/or MAB215, more preferably with an at least 15-fold lower IC 50 value than the reference antibody BVD2-21C1 1 and/or MAB215, more preferably with an at least 20-fold lower IC 50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 30-fold lower IC 50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 50-fold lower IC 50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 100-fold lower IC 50
  • Antibodies of the invention are not limited to the specific peptide sequences provided herein. Rather, the invention also embodies variants of these polypeptides. With reference to the instant disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while appreciating that variants having the ability to block the interaction of GM-CSF to the alpha chain of the GM-CSF receptor fall within the scope of the present invention. As used in this context, "ability to block the interaction of GM- CSF to the alpha chain of the GM-CSF receptor" means a functional characteristic ascribed to an anti-GM-CSF antibody of the invention.
  • a variant can include, for example, an antibody that has at least one altered complementarity determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-a-vis a peptide sequence disclosed herein.
  • CDR complementarity determining region
  • FR framework
  • An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs.
  • the antigen- binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and can also play an important role in antigen binding.
  • the skilled worker routinely can generate mutated or diversified antibody sequences, which can be screened against the antigen, for new or improved properties, for example.
  • Tables 2a (VH) and 2b (VL) delineate the CDR and FR regions for certain antibodies of the invention and compare amino acids at a given position to each other and to corresponding consensus or "master gene" sequences (as described in U.S. Patent No. 6,300,064):
  • the original HuCAL ® master genes have been constructed with their authentic N-termini, e.g. VL lambda 3 contains the amino acids "SY” at position 1 and 2; and VH3 contains the amino acid "E” at position 1.
  • VL lambda 3 contains the amino acids "SY” at position 1 and 2
  • VH3 contains the amino acid "E” at position 1.
  • the HuCAL ® Fab libraries including the HuCAL GOLD ® library, the first two amino acids have been changed to "DI” in the VL lambda 3 chain; and the first amino acid has been changed to "Q" in the VH3 chain.
  • variants are constructed by changing amino acids within one or more CDR regions; a variant might also have one or more altered framework regions.
  • candidate residues that can be changed include e.g. residues 27 or 51 of the variable light and e.g. residues 32 or 56 of the variable heavy chains of MOR04251, since these are positions of variance vis-a-vis each other.
  • Alterations also may be made in the framework regions. For example, a peptide FR domain might be altered where there is a deviation in a residue compared to a germline sequence.
  • candidate residues that can be changed include e.g. residues 27, 50 or 90 of the variable light chain of MOR04251 compared to VL ⁇ 3 and e.g. residues 33, 52 or 96 of the variable heavy chain of MOR04251 compared to VH3.
  • residues 27, 50 or 90 of the variable light chain of MOR04251 compared to VL ⁇ 3 e.g. residues 33, 52 or 96 of the variable heavy chain of MOR04251 compared to VH3.
  • the skilled worker could make the same analysis by comparing the amino acid sequences disclosed herein to known sequences of the same class of such antibodies, using, for example, the procedure described by Knappik et al. (2000), and U.S. Patent No. 6,300,064 issued to Knappik et al.
  • variants may be obtained by using one MOR as starting point for optimiza- tion by diversifying one or more amino acid residues in the MOR, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants for variants with improved properties.
  • Particularly preferred is diversification of one or more amino acid residues in CDR-3 of VL, CDR-3 of VH, CDR-I of VL and/or CDR- 2 of VH. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekas et al., 1994).
  • TAM trinucleotide mutagenesis
  • Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, i.e., "conservative substitutions,” may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
  • nonpolar (hydrophobic) amino acids include alanine, leucine, iso- leucine, valine, proline, phenylalanine, tryptophan, and methionine;
  • polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and gluta- mine;
  • positively charged (basic) amino acids include arginine, lysine, and histidine;
  • negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d).
  • glycine and proline may be substituted for one another based on their ability to disrupt ⁇ -helices. Simi- larly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in ⁇ -helices, while valine, iso- leucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in ⁇ -pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns.
  • sequence identity indicates the percentage of amino acids that are identical between the sequences.
  • Sequence ho- mology indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions.
  • Preferred polypeptide sequences of the invention have a sequence identity in the CDR regions of at least 60%, more preferably, at least 70% or 80%, still more preferably at least 90% and most preferably at least 95%.
  • Preferred antibodies also have a sequence homology in the CDR regions of at least 80%, more preferably 90% and most preferably 95%.
  • the present invention also relates to the DNA molecules that encode an antibody of the invention. These sequences include, but are not limited to, those DNA molecules set forth in Figures 1 a and 2a. DNA molecules of the invention are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants within the invention may be described by reference to their physical properties in hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is double stranded, its equivalent or homolog, using nucleic acid hybridization techniques. It also will be recog- nized that hybridization can occur with less than 100% complementarity. However, given appropriate choice of conditions, hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe.
  • Structural similarity between two polynucleotide sequences can be expressed as a function of "stringency" of the conditions under which the two sequences will hybridize with one another.
  • stringency refers to the extent that the conditions disfavor hybridization. Stringent conditions strongly disfavor hybridization, and only the most structurally related molecules will hybridize to one another under such conditions. Conversely, non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness.
  • Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the "binding" phase and the “washing” phase.
  • the probe is bound to the target under conditions favoring hybridization.
  • Stringency is usually controlled at this stage by altering the temperature.
  • the temperature is usually between 65 0 C and 70°C, unless short ( ⁇ 20 nt) oligonucleotide probes are used.
  • a representative hybridization solution com- prises 6X SSC, 0.5% SDS, 5X Denhardt's solution and 100 ⁇ g of nonspecific carrier DNA. See Ausubel et al, section 2.9, supplement 27 (1994). Of course, many different, yet functionally equivalent, buffer conditions are known. Where the degree of relatedness is lower, a lower temperature may be chosen.
  • Low stringency binding temperatures are between about 25 0 C and 4O 0 C.
  • Medium stringency is between at least about 4O 0 C to less than about 65°C.
  • High stringency is at least about 65 0 C.
  • washing solutions typically contain lower salt concentrations.
  • One exemplary medium stringency solution contains 2X SSC and 0.1% SDS.
  • a high stringency wash solution contains the equivalent (in ionic strength) of less than about 0.2X SSC, with a preferred stringent solution containing about 0.1 X SSC.
  • the temperatures associated with various stringencies are the same as discussed above for "binding.”
  • the washing solution also typically is replaced a number of times during washing. For example, typical high stringency washing conditions comprise washing twice for 30 minutes at 55° C and three times for 15 minutes at 60° C.
  • the present invention includes nucleic acid molecules that hybridize to the molecules of set forth in Figures Ia and 2a under high stringency binding and washing conditions, where such nucleic molecules encode an antibody or functional fragment thereof having properties as described herein.
  • Preferred molecules are those that have at least 75% or 80% (preferably at least 85%, more preferably at least 90% and most preferably at least 95%) homology or sequence identity with one of the DNA molecules described herein.
  • variants of DNA molecules provided herein can be constructed in several different ways. For example, they may be constructed as completely synthetic DNAs. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel et al, section 2.11, Supplement 21 (1993). Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana et al, J. MoI. Biol. 72:209-217 (1971); see also Ausubel et al, supra, Section 8.2. Synthetic DNAs preferably are designed with convenient restriction sites engineered at the 5' and 3' ends of the gene to facilitate cloning into an appropriate vector.
  • a method of generating variants is to start with one of the DNAs dis- closed herein and then to conduct site-directed mutagenesis. See Ausubel et al., supra, chapter 8, Supplement 37 (1997).
  • a target DNA is cloned into a single-stranded DNA bacteriophage vehicle.
  • Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alter ation(s).
  • the complementary strand is synthesized and the double stranded phage is introduced into a host.
  • Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing.
  • various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants.
  • the present invention further provides recombinant DNA constructs comprising one or more of the nucleotide sequences of the present invention.
  • the recombinant constructs of the present invention are used in connection with a vector, such as a plasmid, phagemid, phage or viral vector, into which a DNA molecule encoding an antibody of the invention is inserted.
  • the encoded gene may be produced by techniques described in Sambrook et al., 1989, and Ausubel et al, 1989.
  • the DNA sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in OLIGONUCLEOTIDE SYNTHESIS (1984, Gait, ed., IRL Press, Oxford), which is incorporated by reference herein in its entirety.
  • Recombinant constructs of the invention are comprised with expression vectors that are capable of expressing the RNA and/or protein products of the encoded DNA(s).
  • the vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF).
  • the vector may further comprise a selectable marker sequence. Specific initiation and bacterial secretory signals also may be required for efficient translation of inserted target gene coding sequences.
  • the present invention further provides host cells containing at least one of the DNAs of the present invention.
  • the host cell can be virtually any cell for which expres- sion vectors are available. It may be, for example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell or a prokaryotic cell, such as a bacterial cell.
  • Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, elec- troporation or phage infection.
  • Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
  • the vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the host.
  • Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus.
  • Bacterial vectors may be, for example, bacteriophage-, plasmid- or phagemid-based. These vectors can contain a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017). Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is de-repressed/induced by appropriate means ⁇ e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifu- gation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
  • appropriate means e.g., temperature shift or chemical induction
  • a number of expression vectors may be advantageously selected depending upon the use intended for the protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • Therapeutic methods involve administering to a subject in need of treatment a therapeutically effective amount of an antibody contemplated by the invention.
  • a "therapeutically effective" amount hereby is defined as the amount of an antibody that is of suf- ficient quantity to effectively block the interaction between GM-CSF and its receptor in a treated area of a subject — either as a single dose or according to a multiple dose regimen, alone or in combination with other agents, which leads to the alleviation of an adverse condition, yet which amount is toxicologically tolerable.
  • the subject may be a human or non-human animal ⁇ e.g., rat or rhesus).
  • An antibody of the invention might be co-administered with known medicaments, and in some instances the antibody might itself be modified.
  • an antibody could be conjugated to an immunotoxin or radioisotope to potentially further increase efficacy.
  • inventive antibodies can be used as a therapeutic or a diagnostic tool in a variety of situations where GM-CSF is undesirably expressed or found.
  • Disorders and conditions particularly suitable for treatment with an antibody of the inventions are inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis or shock.
  • RA rheumatoid arthritis
  • pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients.
  • An antibody of the invention can be administered by any suitable means, which can vary, depending on the type of disorder being treated. Possible administration routes include parenteral (e.g., intramus- cular, intravenous, intraarterial, intraperitoneal, or subcutaneous), intrapulmonary and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration.
  • an antibody of the invention might be administered by pulse infusion, with, e.g., declining doses of the antibody.
  • the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
  • the amount to be administered will depend on a variety of factors such as the clinical symptoms, weight of the individual, whether other drugs are administered. The skilled artisan will recognize that the route of administration will vary depending on the disorder or condition to be treated.
  • Determining a therapeutically effective amount of the novel polypeptide largely will depend on particular patient characteristics, route of administration, and the nature of the disorder being treated. General guidance can be found, for example, in the publications of the International Conference on Harmonisation and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, pp. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). More specifically, deter- mining a therapeutically effective amount will depend on such factors as toxicity and efficacy of the medicament. Toxicity may be determined using methods well known in the art and found in the foregoing references. Efficacy may be determined utilizing the same guidance in conjunction with the methods described below in the Examples.
  • GM-CSF is expressed by various cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells; thus, an anti-GM-CSF antibody of the invention may be employed in order to image or visualize a site of possible accumulation of GM-CSF in different tissues in a patient.
  • an antibody can be de- tectably labeled, through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.) fluorescent labels, paramagnetic atoms, etc. Procedures for accomplishing such labeling are well known to the art. Clinical application of antibodies in diagnostic imaging are reviewed by Grossman, H. B., Urol. Clin. North Amer.
  • the detection of foci of such detectably labeled antibodies might be indicative of a site of inflammation, for example.
  • this examination is done by removing samples of tissue or blood and incubating such samples in the presence of the detectably labeled antibodies.
  • this technique is done in a noninvasive manner through the use of magnetic imaging, fluorography, etc.
  • Such a diagnos- tic test may be employed in monitoring the success of treatment of diseases, where presence or absence of GM-CSF is a relevant indicator.
  • the invention also contemplates the use of an anti- GM-CSF antibody, as described herein for diagnostics in an ex vivo setting.
  • the antibodies of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, wherein an antibody of the invention (including any functional fragment thereof) is combined in a mixture with a pharmaceutically acceptable carrier vehicle.
  • Suitable vehicles and their formulation are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990).
  • REMINGTON'S PHARMACEUTICAL SCIENCES 18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990.
  • Such compositions will contain an effective amount of one or more of the antibodies of the present invention, to- gether with a suitable amount of carrier vehicle.
  • Preparations may be suitably formulated to give controlled-release of the active compound.
  • Controlled-release preparations may be achieved through the use of polymers to complex or absorb anti- GM-CSF antibody.
  • the controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, poly- vinyl, pyrrolidone, ethylenevinyl-acetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release.
  • Another possible method to control the duration of action by controlled release preparations is to incorporate anti-GM-CSF antibody into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
  • a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
  • Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampules, or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • HuCAL GOLD ® library was amplified in 2xYT medium containing 34 ⁇ g/ml chloramphenicol and 1 % glucose (2x YT-CG). After helper phage infection (VCSM 13) at an OD 6O0 of 0.5 (30 min at 37°C without shaking; 30 min at 37 0 C shaking at 250 rpm), cells were spun down (4120 g; 5 min; 4°C), resuspended in 2xYT / 34 ⁇ g/ml chloramphenicol / 50 ⁇ g/ml kanamycin / 0.25mM IPTG and grown overnight at 22 0 C.
  • helper phage infection VCSM 13
  • OD 6O0 OD 6O0
  • Phages were PEG- precipitated from the supernatant, resuspended in PBS / 20 % glycerol and stored at -8O 0 C. Phage amplification between two panning rounds was conducted as follows: mid- log phase E. coli TGl cells were infected with eluted phages and plated onto LB-agar supplemented with 1 % of glucose and 34 ⁇ g/ml of chloramphenicol. After overnight incubation at 3O 0 C, colonies were scraped off and used to inoculate 2x YT-CG until an OD ⁇ oonm of 0.5 was reached and helper phage added as described above.
  • HuCAL GOLD ® antibody-phages were divided into three pools comprising different VH master genes. These pools were individually subjected to either a) a solid phase panning on biotinylated human GM-CSF protein (custom made by R&D Systems, Minneapolis, MN) directly coated on neutravidin coated 96well plates (Pierce, Rockford, IL) as solid support for three rounds or b) a solution panning on biotinylated human GM-CSF protein captured onto streptavidin coated Dynabeads (Dynal, Oslo, Norway) for three rounds.
  • HuCAL GOLD ® phages Prior to the selections, 100 ⁇ l of HuCAL GOLD ® phages were pre-adsorbed in lOO ⁇ l blocking buffer containing 0.4 ⁇ l 25% Tween20 for 0.5 h at RT. Blocked phages were transferred in lOO ⁇ l aliquots to wells of a neutravidin plate for 0.5 h at RT. This step was repeated twice for pre-absorption.
  • Bound phages were eluted by adding 120 ⁇ l of 20 mM DTT in 10 mM Tris pH 8.0 per well for 10 min at RT. The eluate was removed and added to 14 ml E. coli TGl grown to an OD ⁇ oo nm of 0.6-0.8. Wells were additionally washed with 200 ⁇ l PBS and this solution was also added to the TGl cells. Phage infection of E. coli was allowed for 45 min at 37 0 C without shaking. Additionally, 200 ⁇ l of TGl cells grown to an OD 60 o nm of 0.6-0.8 were added to the selection wells for 45 minutes at 37 0 C without shaking.
  • TG-I cells were added to the 14ml culture already containing the phages from the first elution step. After centrifugation for 10 min at 5000rpm, the bacterial pellets were each resus- pended in 500 ⁇ l 2xYT medium, plated on 2x YT-CG agar plates and incubated overnight at 3O 0 C. Colonies were then scraped from the plates and phages were rescued and amplified as described above.
  • the second and third rounds of selection were performed in an identical way to the first round of selection with the only difference that the washing conditions after binding of phage were more stringent. Additionally, in the third round of selection, phages were submitted to an additional preadsorption step on streptavidin-coated beads (Dynabeads M-280; Dynal). Eppendorf tubes were blocked with Chemiblocker solution by incubation for 30 min at RT. Of each phage pool 0.3ml were mixed 1 : 1 with 2xChemiblocker solution containing 0.05% Tween20 and incubated for Ih at RT in the blocked Eppendorf tubes on a rotator.
  • Blocked phages were then transferred to newly blocked Eppendorf tubes and 50 ⁇ l of Dynabeads M-280 were added for another 30min for preadsorption. Beads were removed using a magnetic device (Dynal MPC-E). Aliquots of 150 ⁇ l of phages were then transferred to neutravidin plates for further preadsorption as in round 1 and 2 (see above).
  • Phages diluted in 500 ⁇ l PBS for each panning condition were mixed with 500 ⁇ l 2xChemiblocker / 0.1% Tween 1 h at RT (rotator). Preadsorption of phages was performed twice: 50 ⁇ l of blocked Streptavidin magnetic beads were added to the blocked phages and incubated for 30 min at RT on a rotator. After separation of beads via a magnetic device (Dynal MPC-E) the phage supernatant ( ⁇ lml) was trans- ferred to a new blocked tube and preadsorption was repeated on 50 ⁇ l blocked beads for 30 min.
  • biotinylated hGM-CSF was added to blocked phages in a new blocked 1.5 ml tube and incubated for 1 h at RT on a rotator.
  • 100 ⁇ l of blocked streptavidin magnetic beads were added to each panning phage pool and incubated 10 min at RT on a rotator.
  • Phage bound to biotinylated GM-CSF and therefore immobilized to the magnetic beads were collected with a magnetic particle separator (Dynal MPC-E). Beads were then washed 7x in PBS/0.05% Tween using a rotator, followed by washing another three times with PBS.
  • Elution of phage from the Dynabeads was performed adding 300 ⁇ l 2OmM DTT in 1 OmM Tris/HCl pH8 to each tube for 10 min. Dynabeads were removed by the magnetic particle separator and the supernatant was added to 14ml of a E.coli TG-I culture grown to OD 600 n m of 0.6-0.8. Beads were then washed once with 200 ⁇ l PBS and PBS containing additional removed phage was added to the 14 ml E.coli TG-I culture.
  • the bacterial pellets were each resuspended in 500 ⁇ l 2xYT medium, plated on 2x YT-CG agar plates and incubated overnight at 30°C. Colonies were then scraped from the plates and phages were rescued and amplified as described above.
  • the second and third rounds of the solution panning on biotinylated GM-CSF was performed according to the protocol of the first round except for increasing the stringency of the washing procedure.
  • the Fab encoding inserts of the selected HuCAL GOLD ® phagemids were subcloned into the expression vector pMORPH ® X9_Fab_FH (Fig 5) to facilitate rapid expression of soluble Fab.
  • the DNA of the selected clones was digested with Xbal and EcoKL, thereby cutting out the Fab encoding insert (ompA-VLCL and phoA-Fd), and cloned into the
  • Fabs expressed in these vectors carry two C-terminal tags (FLAGTM and 6xHis, respectively) for detection and purification.
  • BEL buffer (2xBBS/EDTA: 24.7 g/1 boric acid, 18.7 g NaCl/1, 1.49 g EDTA/1, pH8) was added containing 2.5 mg/ml lysozyme and incubated for 1 h at 22 0 C on a microtiter plate shaker (400 rpm).
  • BEL extracts were used for binding analysis by ELISA or a BioVeris M-series ® 384 analyzer (see Example 2).
  • Fab fragments encoded by pMORPH ® X9 Fab_FH in TG-I cells were carried out in shaker flask cultures with 1 1 of 2xYT medium supplemented with 34 ⁇ g/ml chloramphenicol. After induction with 0.5 mM IPTG, cells were grown at 22°C for 16 h. Whole cell extracts of cell pellets were prepared by French Press and Fab fragments isolated by nickel/NTA chromatography (Qiagen, Hilden, Germany). Concentrations were determined by UV-spectrophotometry (Krebs et al., 2001).
  • BEL extracts of individual E. coli clones selected by the above mentioned panning strategies were analyzed by ELISA or BioVeris (BioVeris M-series ® 384 analyzer) in order to identify clones encoding hGM-CSF specific Fabs.
  • BEL extract was diluted at least 1 :50 and maximally 1 :1000 in assay buffer (PBS/0,05%Tween20/0.5%BSA) for use in BioVeris screening.
  • Biotinylated GM-CSF R&D Systems
  • Dynabeads Dy- nal
  • Per well of a 96 or 384 well plate 25 or 15 ⁇ l of a 1:25 dilution of the Dynabead-stock solution was used. Beads were washed three times with assay buffer before adding biotinylated GM-CSF for 30 min at RT on a shaker.
  • Anti-human (Fab) ' 2 (Dianova) was ruthenium labelled using the BV-tagTM (BioVeris Europe, Witney, Oxfordshire, UK). This secondary antibody was added to the GM-CSF coupled beads at a concentration of 6 ⁇ g/ml immediately before use. lOO ⁇ l or 60 ⁇ l of diluted BEL extract (see above) of E.
  • coli expression cultures containing Fab antibodies was filled into wells of a 96 or 384 well plate and, respectively, 25 or 15 ⁇ l of the GM-CSF coupled beads plus anti-Fab-BV-tagTM secondary antibody mix was added to each well and incubated for 2h at RT on a plate shaking device. The plates were analyzed in a BioVeris M-SERIES ® 384 Analyzer.
  • Crossreactivity of the anti-hGM-CSF antibodies was determined to the following ana- lytes: rat and mouse GM-CSF, human IL-3, human IL-4, , human IL-5, , human IL-13, , human M-CSF (all from Peprotech, London, UK). This was performed in a capture set-up by surface plasmon resonance (Biacore 3000, Uppsala, Sweden).
  • CM5 chips (Biacore, Sweden) were coated with 5000-6000RU anti-F(ab) 2 (Dianova, Af- finipure F(ab) 2 Fragment Goat Anti-Human IgG, F(ab) 2 Fragment specific); 80 ⁇ g/ml 1OmM acetate buffer, pH4 on all 4 flow cells, using standard EDC-NHS amine coupling chemistry.
  • the analyte growth factor was injected (20 ⁇ l, flow rate 20 ⁇ l/min) at a concentration range between 15 and 200OnM for the determination of the specific signal. Afterwards the achieved buffer sensogram was manually subtracted from the specific one. After each cycle, the flow cells were regenerated with 10OmM HCl (5 ⁇ l).
  • HuCAL ® anti-tiGM-CSF antibodies including MOR03684 and MOR03682 were tested and were specific for human GM-CSF and did not bind to any of the other cytoki- nes or mouse or rat GM-CSF .
  • Fab MOR03929 showed significant cross reactivity to rat GM-CSF.
  • Example 3 Identification of anti-human GM-CSF Fab candidates that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha
  • hGM-CSF specific antibodies which were selected from the HuCAL GOLD ® library were tested for the potency to inhibit the interaction between hGM-CSF and its receptor.
  • the interaction was tested in two ways, (i) one being a proliferation assay using the GM-CSF dependent TF-I cell line (Kitamura et al., 1989) and (ii) the other being a FACS analysis with a recombinant CHO cell line expressing the alpha chain of the GM- CSF receptor.
  • the TF-I proliferation assay the ability of the anti-GM-CSF antibodies to block the interaction of GM-CSF with the endogenous GM-CSF receptor consisting of the alpha and beta chain was analyzed leading to reduction in cell proliferation.
  • the FACS assay the specific inhibition of the interaction between GM-CSF and the alpha chain of the GM-CSF receptor was determined.
  • the cDNA of human GM-CSF (Genbank accession num- ber NP_000749 ) was cloned by RT-PCR technique from RNA isolated from 1x10e7 TF- 1 cells using the RNeasy kit from Qiagen (Hilden, Germany). Reverse transcription was performed with the SuperscriptII kit using random hexamers (Gibco) followed amplification of the GM-CSF cDNA by PCR. The obtained PCR-product was cloned into expression vector pcDNA3.1(+) yielding pcDNA-huGM-CSF.
  • HEK293 cells were transiently transfected with these expression vectors respectively using lipofectamine (Stratagene, LaJoIIa, USA).
  • lipofectamine Stratagene, LaJoIIa, USA.
  • the medium containing the secreted recombinant macaca or human GM-CSF was harvested 4 days after transfection.
  • TF-I (Kitamura et al., 1989) cells were grown according to the provider's protocol (DSMZ, Braunschweig, Germany; DSMZ No. ACC 334). TF-I cells were washed twice with RPMI 1640 medium (10% FCS) and then seeded at a concentration of 2 x 10 5 cells/ml in 50 ⁇ l per well of a flat bottom 96well cell culture dish.
  • GM-CSF Human recombinant GM-CSF ("Leucomax", ESSEX Pharma, M ⁇ nchen) at 0.5ng/ml and HuCAL ® Fab antibodies (200ng/ml - 200 ⁇ g/ml diluted in RPMI 1640 medium, 10% FCS) were mixed for 30 min and 50 ⁇ l of the mix was added to the TF-I cells, so that the final concentration of GM-CSF was 0.25ng/ml. Maximal cell proliferation (0% inhibition) was measured incubating TF-I cells at a final GM-CSF of concentration of 0.25ng/ml, without the addition of antibody.
  • TF-I proliferation 100% inhibition of TF-I proliferation was measured by omitting GM-CSF from the assay and keeping the cells in RPMI 1640 medium (10% FCS) only. TFl cells were then incubated for 72 hours at 37 0 C with 5% CO 2 in a humidified chamber. Cell vitality was measured by adding MTT or XTT reagent (Roche, Mannheim, Germany) according to the manufacturer's recommendation. Overall 19 Fab were identified that showed significant inhibition of TF-I proliferation.
  • the binders MOR03682, MOR03684 and MOR03929 showed consistent inhibition of TFl cell proliferation of greater than 50% at a concentration of 2 ⁇ M.
  • TF-I proliferation assay instead of adding purified human GM-CSF to the TF-I cells a supernatant of trans- fected HEK293 cells that secrete recombinant macaca GM-CSF into the medium was used. TF-I cells proliferated in the presence of macaca GM-CSF containing supernatant but not in the presence of supernatant from untransfected HEK293 cells.
  • GM-CSF GM-CSF receptor alpha chain
  • cDNA was cloned into an expression vector and stably transfected into CHO- Kl cells (DSMZ ACC 110).
  • N-GCRa-plusSS TTCTCTGGATCCGCCACCATGCTTCTCCTGGTGACAAGCC
  • C-flGCRa ACCCTCCAATTGTCAGGTAATTTCCTTCACGGTC.
  • the PCR reaction yielded a product of ⁇ 1250bp which was digested with EcoRI and BamHl (New England BioLabs).
  • the expression vector pcDNA3.1(+) (Invitrogen, Paisley, UK) was digested with the same enzymes. After purification of the digested vector and PCR product, the fragments were ligated and transformed by electroporation into E.coli DHlOB cells. Correct clones were identified after preparation of plasmid DNA and sequencing. Correct clones (pcDNA3.1(+)-GM-CSFRalpha) contained the full length human GM-CSF receptor alpha cDNA.
  • CHO-Kl cells were grown according to the provider's protocol (DSZM, Braunschweig, Germany; DSMZ No. ACC 110).
  • DSMZ No. ACC 110 For transfection cells were grown to 80% confluence in a 6- well plate and incubated with 5 ⁇ g DNA of pcDNA3.1(+)-GM-CSFRalpha mixed with lO ⁇ l of the Lipofectamine 2000 reagent (Invitrogen). After 48h cells were fed with lmg/ml G418 (Gibco) and after another 24h medium was replaced with such containing 2mg/ml G418. After two weeks single cells were seeded into wells of a 96-well culture dish.
  • Single clones were grown up and 5x10 5 cells of each clone were tested for GM- CSFR-alpha expression by FACS analysis using murine IgG MAB 1006 (Chemicon International, Temecula, CA) as primary antibody at a concentration of l ⁇ g/ml and (R-PE- AffiniPure (Fab') 2 Goat-anti-mouse-IgG (Dianova) as secondary antibody at a 1 :200 dilution. Primary and secondary antibodies were incubated with the cells for Ih sequen- tially, while cells were washed in FACS buffer (PBS, 3%FCS) between these steps. Fluorescence of stained cells was quantified in the FL2 channel using a FACSCalibur system (Becton Dickinson).
  • antibodies at increasing concentrations Prior to adding to cells, antibodies at increasing concentrations (0.1 to 100 ⁇ g/ml) were co-incubated with biotinylated GM-CSF (0.5 ⁇ g/ml) in FACS buffer (PBS/3%FBS/NaN 3 0,05%) for 30min at RT.
  • Fab antibodies MOR03682, MOR03684 and MOR03929 showed significant inhibition of GM-CSF binding to the cell surface expressed GM-CSF receptor alpha.
  • Example 4 Affinity maturation of selected Fab by stepwise exchange of CDR cassettes
  • clones MOR03682, MOR03684 and MOR03929 were subjected to affinity maturation.
  • CDR regions were optimized by cassette mutagenesis using trinucleotide directed mutagenesis (VirnekSs et ah, 1994; Nagy et al., 2002). Sequence analysis revealed no sequence homology between the CDRs of the three parental clones analyzed.
  • Table 2a and 2b provide the six CDR peptide sequences for the parental clones MOR03682, MOR03684 and MOR03929.
  • Fab fragments from expression vector pMORPH ® X9Fab_FH were cloned into a phagemid vector (US 6,753,136). Then, two different strategies were applied to optimize the affinity and effi- cacy of the parental Fabs.
  • phage antibody Fab library was generated where the L-CDR3 of each parental was replaced by a repertoire of individual lambda light chain CDR3 sequences.
  • H-CDR2 region was replaced by a repertoire of individual heavy chain CDR2 sequences.
  • Affinity maturation libraries were generated by transforming the diversified clones into E. coli TOPlOF' (Invitrogen). Phages were prepared as described in Example IA.
  • Electrochemilu- minescence (ECL) based affinity determination in solution and data evaluation were basically performed as described by Haenel et al., 2005: A constant amount of Fab was equilibrated with different concentrations (serial 5" dilutions) of human GM-CSF (Leu- comax) in solution.
  • Biotinylated human GM-CSF R&D Systems coupled to paramag- netic beads (M-280 Streptavidin, Dynal) and BV -tagTM (BioVeris Europe, Witney, Ox- forfshire, UK) labeled anti-human (Fab)' 2 (Dianova) was added and incubated for 15 - 30 min. Subsequently, the concentration of unbound Fab was quantified via ECL detection using a M- SERIES ® 384 analyzer (BioVeris Europe).
  • Association phase was set to 60 s and dissociation phase to 120 s (parental) or up to 600 s (affinity optimized).
  • dissociation phase was set to 60 s and dissociation phase to 120 s (parental) or up to 600 s (affinity optimized).
  • the following conditions basically according to Drake et al., (2004) were used: Fab was applied in a single concentration of 200 nM; flow rate was set to 100 ⁇ l/min and dis- sociation phase to 6000 - 18.000 s.
  • affinities for the Fabs were estimated, which are shown in table 4.
  • Table 4 Affinities of anti-hGM-CSF Fabs determined by Biacore and solution equilibrium titration (SET)
  • Example 5 Characterization of optimized anti-human GM-CSF Fabs that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha chain A. GM-CSF receptor alpha binding assay
  • the GM-CSF receptor binding assay was performed as described above (Example 3C) using 0.5 ⁇ g/ml (35nM) of biotinylated GM-CSF. Maximal binding of GM-CSF to CHO- GMRa#l l cells (0% inhibition) was measured by incubating cells at a final GM-CSF concentration of 0.5 ⁇ g/ml of biotinylated GM-CSF, without the addition of antibody. 100% inhibition of GM-CSF binding was measured by omitting GM-CSF from the assay. IC5 0 values were determined from the dose response curves obtained using GraphPad
  • This assay qualitatively showed that the Fabs obtained from affinity maturation and X- cloning prevent GM-CSF from binding to the GM-CSF receptor alpha chain and therefore retained the blocking mechanism of their parental Fabs.
  • the assay needed to be performed with a concentration of 35nM (0.5 ⁇ g/ml) biotinylated GM-CSF in order to obtain a significant signal in FACS. Therefore 17.5 nM Fab (or 8.75 nM IgG) is theoretically needed to block 50% of the GM-CSF, thus setting a limit for determination of IC 50 values.
  • TF-I proliferation assay was performed as described in Example 3B. Fab with improved affinities and the parental Fabs as well as monoclonal reference IgGs were analyzed. IC 50 values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 6 summarizes the ICs 0 values obtained in these assays.
  • Table 6 IC 50 values of anti-hGM-CSF Fabs and control IgGs in TF-I proliferation assay
  • IC 50 values in the TF-I proliferation assay were determined for the parental Fab MOR03682, its affinity matured derivatives MOR04283, MOR04297 and the x-cloned variant MOR04342. Table 7 summarizes the IC 50 values obtained in these assays.
  • Table 7 IC 50 values of anti-hGM-CSF Fabs in TF-I proliferation assay
  • variable domain fragments of the gene optimized heavy (VH) and light chains (VL) were subcloned from the pPCR-Script vectors (Example5a) into the the pMORPH ® 2_h_Ig vector series for human IgGl.
  • Codon-optimized VH of MOR04357 was isolated from 055906pPCR-Script via NheVBlpl digestion and inserted into pMorph2_h_IgG If master vector cut with the same restriction enzymes. This vector already contained a human gamma 1 constant region.
  • the resulting expression plasmid was termed pMorph2_h_IgGlf_MOR04357_co.
  • Codon-optimized VL of MOR04357 was isolated from 055907pPCR-Script via NheVHpal digestion and inserted into pMorph2_h_Iglambda2 master vector cut with the same restriction enzymes. This vector already contained a human lambda constant region. The resulting expression plasmid was termed pM2_h_Iglambda2_MOR04357_co.
  • Eukaryotic HKBI l cells were transfected with an equimolar amount of IgG heavy and light chain expression vector DNA.
  • Cell culture supernatant was harvested from 3 to 7 days post transfection. After adjusting the pH of the supernatant to 8.0 and sterile filtration, the solution was subjected to standard protein A affinity chromatography (rProteinA FF or MabSelect SURE, GE Healthcare). Buffer exchange was performed to 1 x Dulbcecco's PBS (pH 7,2, Invitrogen) and samples were sterile filtered (0,2 ⁇ m).
  • MOR04357 IgGl was dialysed against 1 x Dulbcecco's PBS (pH 6,5, Invitrogen). Purity of IgG was analysed under denaturing, reducing conditions in SDS-PAGE or by using Agilent BioAnalyzer and in native state by SE- HPLC.
  • Affinity determination to rat GM-CSF was done essentially as described in Example 4D using rat-GM-CSF (Peprotech) as analyte in solution instead of human GM-CSF. Affinities were calculated according to Haenel et al (2005). The K D value for the MOR04357 IgGl against rat recombinant GM-CSF was determined to be 130 pM.
  • Example 7 Characterization of MOR04357 IgGl derived from optimized anti-human GM-CSF Fabs
  • TF-I proliferation assay was performed as described in Example 3B. MOR04357 was analyzed in IgGl format and as control monoclonal reference IgGs were analyzed. IC50 values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 8 summarizes the IC 5 0 values obtained in these assays. Three different variants of GM-CSF were used in this assay: Firstly, recombinant human GM-CSF at a concentration of 0.25 ng/ml, produced in E.
  • coli secondly, culture supernatant from HEK293 which have been transiently transfected with pcDNA-huGM-CSF (see Example 3A), containing recombinant human GM-CSF and thirdly, culture supernatant from HEK293 cells which have been transiently transfected with pcDNA-macGM-CSF (see Example 3A), containing recombinant macaca mulatto (rhesus) GM-CSF.
  • TF-I proliferation assays the HEK293 culture supernatants were used as a source of the respective GM- CSF in such dilutions that TF-I cells showed a similar proliferation as compared to prolifera- tion given at the defined concentration of 0.25 ng/ml purified recombinant human GM-CSF produced in E. coli.
  • Table 8 IC 50 values of MOR04357 IgG and control IgGs in TF-I proliferation assay IC 50 (pM) human human macaca
  • Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 90, 1414-1424.
  • Granulocyte- macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine 2, 60-67.
  • Granulocyte- macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol 171, 6846-6855.
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • GM-CSF Granulocyte-macrophage colony- stimulating factor
  • G-CSF granulocyte colony-stimulating factor
  • DCs Dendritic cells
  • RA rheumatoid arthritis
  • progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate ThI inflammatory-type responses.
  • Signal transduction by the high-affinity GM-CSF receptor two distinct cytoplasmic regions of the common beta subunit responsible for different signaling.
  • GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU. Immunity 75, 557-567.
  • GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Description

Anti-GM-CSF Antibodies and Uses Therefor
BACKGROUND OF THE INVENTION
Granulocyte-macrophage colony stimulating factor, GM-CSF, was originally identified as a hemopoietic growth factor. It is produced by a number of cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells (Metcalf et al., 1986; Clark and Kamen, 1987; Hart et al, 1988; Metcalf et al., 1986). In addition to having a function of growth stimulation and differentiation on hemopoietic precursor cells, GM-CSF also was discovered as having a variety of effects on cells of the immune system expressing the GM-CSF receptor (for review see: Hamilton, 2002; de Groot et al., 1998). The most important of these functions is the activation of monocytes, macrophages and granulocytes in several immune and inflammatory processes (Gasson et al., 1990b; Gasson et al., 1990a; Hart et al., 1988; Rapoport et al., 1992).
Mature GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The variable degree of glycosylation results in a molecular weight range between 14kDa and 35kDa. Non-glycosylated and glycosylated GM-CSF show similar activity in vitro (Cebon et al., 1990). The crystallographic analysis of GM-CSF revealed a barrel- shaped structure composed of four short alpha helices (Diederichs et al., 1991). The overall folding is similar to other growth factors like growth hormone, interleukin-2 and in- terleukin-4.
GM-CSF exerts its biological activity by binding to its receptor (Kastelein and Sha- nafelt, 1993; Sisson and Dinarello, 1988). The most important sites of GM-CSF receptor (GM-CSF-R) expression are on the cell surface of myeloid cells and endothelial cells, whereas lymphocytes are GM-CSF-R negative. The native receptor is composed of at least two subunits, alpha and beta. The alpha subunit imparts ligand specificity and binds GM-CSF with nanomolar affinity (Gearing et al., 1989; Gasson et al., 1986). The beta subunit is also part of the interleukin-3 and interleukin-5 receptor complexes and, in association with the GM-CSF receptor alpha subunit and GM-CSF, leads to the formation of a complex with picomolar binding affinity (Hayashida et al., 1990). The binding domains on GM-CSF for the receptor have been mapped: GM-CSF interacts with the beta subunit of its receptor via a very restricted region in the first alpha helix of GM-CSF (Shanafelt et al., 1991b; Shanafelt et al., 1991a; Lopez et al., 1991). Binding to the alpha subunit could be mapped to the third alpha helix, helix C, the initial residues of the loop joining helices C and D, and to the carboxyterminal tail of GM-CSF (Brown et al., 1994).
Formation of the GM-CSF trimeric receptor complex leads to the activation of com- plex signaling cascades involving molecules of the JAK/STAT families, She, Ras, Raf, the MAP kinases, phosphatidylinositol-3 -kinase and NFkB, finally leading to transcription of c-myc, c-fos and c-jun. Activation is mainly induced by the beta subunit of the receptor (Hayashida et al., 1990; Kitamura et al., 1991; Sato et al., 1993). The shared beta subunit is also responsible for the overlapping functions exerted by IL-3, IL-5 and GM- CSF (for review see: de Groot et al., 1998).
Apart from its hemopoietic growth and differentiation stimulating activity, GM-CSF functions especially as a proinflammatory cytokine. Macrophages and monocytes as well as neutrophils and eosinophils become activated by GM-CSF, resulting in the release of other cytokines and chemokines, matrix degrading proteases, increased HLA expression and increased expression of cell adhesion molecules or receptors for CC-chemokines. The latter, in turn, leads to increased chemotaxis of inflammatory cells into inflamed tissue (Chantry et al., 1990; Hamilton, 2002; Sisson and Dinarello, 1988; Zhang et al., 1998; Hamilton et al., 1993; Lopez et al., 1986; Cheng et al., 2001 ; Gomez-Cambronero et al., 2003). Often, GM-CSF exerts its activity in synergy with other inflammatory stimulating factors like other cytokines or LPS, e.g. neutrophils treated with GM-CSF in combination with e.g. LPS will show increased oxidative burst (Kaufman et al., 1989; Rapoport et al., 1992).
GM-CSF as target for anti-inflammatory therapy:
Due to its diverse activating functions in the immune system, GM-CSF can be con- sidered as a target for anti-inflammatory therapy. Chronic and acute inflammatory diseases like rheumatoid arthritis (RA), multiple sclerosis (MS), Crohn's disease, psoriasis, asthma, atopic dermatitis or shock may well benefit from the blocking of GM-CSF activity and subsequent reduction of harmful activities of GM-CSF responsive cells (Hamilton, 1993; Zhang et al., 1998; Hamilton, 2002).
Arthritis: Several groups showed that GM-CSF, as well as its receptor, are present in the synovial joint of arthritis patients (Alvaro-Gracia et al., 1991; Xu et al., 1989; Haworth et al., 1991). Additionally, GM-CSF was shown to cause flares of rheumatoid arthritis in patients treated with GM-CSF for neutropenia in Felty's syndrome (Hazenberg et al., 1989) or after chemotherapy (de Vries et al., 1991). First hints on the usefulness of antibodies blocking GM-CSF for the treatment of arthritis came from mouse in vivo studies (Campbell et al., 1997; Campbell et al., 1998; Cook et al., 2001). Specifically, Cook et al. showed that neutralizing antibodies to GM- CSF showed efficacy in a collagen-induced arthritis model. Blocking of GM-CSF led to a reduction of disease severity concerning inflammation, cartilage destruction and progres- sion of disease in initially affected limbs or progression to other limbs.
There are several effects of an anti-GM-CSF therapy from which the patients with rheumatoid arthritis or with other inflammatory diseases could benefit.
Blocking GM-CSF is expected to inhibit or reduce: a) the activation and number of mature monocytes, macrophages, and neutro- phils. Especially neutrophils and macrophages are abundant in synovial fluid and membrane. The macrophage number in the synovium has been shown to correlate with the degree of erosion in RA joints (Mulherin et al., 1996; Burmester et al., 1997). Macrophages are the source of a variety of other proinflammatory cytokines and matrix degrading proteases. Production of H2O2 by neutrophils is part of the destructive processes taking place in the arthritic joints (Babior, 2000). b) the differentiation of myeloid dendritic cells (DCs) and activation of synovial DCs (= synoviocytes). GM-CSF upregulates and maintains HLA class II expression on DCs and RA synoviocytes (Alvaro-Gracia JM et al., 1991). DCs are instructed within the joint to acquire functions associated with the selective activation of inflammatory T- cells. Specific HLA-DR alleles have been linked to susceptibility to RA, and activation of T-cells via antigen presentation of DCs may play a crucial role in this type of immune disease (Santiago-Schwarz et al., 2001).
Multiple Sclerosis:
In multiple sclerosis, elevated levels of GM-CSF correlate with the active phase of MS (Carried et al., 1998; McQualter et al., 2001) and GM-CSF-/- mice fail to develop disease in the model system for MS, experimental encephalomyelitis, EAE (McQualter et al., 2001).
Asthma:
In asthma, increased amounts of GM-CSF in the lung have been reported (Broide and Firestein, 1991). At the same time eosinophils are elevated, on which GM-CSF in synergy with interleukin-5 acts in three ways: i) it stimulates the differentiation from progenitor cells into eosinophils, ii) it stimulates their functional activation, and iii) it prolongs the survival of eosinophils in the lung (Broide et al., 1992; Yamashita et al., 2002). Thus, reduction of the survival of eosinophils in asthmatic airways by blocking GM-CSF is likely to ameliorate disease. The usefulness of anti-GM-CSF neutralizing antibodies was further shown in a model for murine asthma where the administration of such antibodies led to significant reduction of airway hyperresponsiveness and airway inflammation (Yamashita et al., 2002).
In a different mouse model, LPS-dependent inflammation of the lung could be re- duced by application of anti-GM-CSF antibody 22E9 in the mouse (Bozinovski et al., 2003).
Toxic effects:
Mice homozygous for a disrupted granulocyte/macrophage colony-stimulating factor (GM-CSF) gene develop normally and show no major perturbation of hematopoiesis up to 12 weeks of age. While most GM-CSF-deficient mice are superficially healthy and fertile, all develop a disorganized vascular extracellular matrix with disrupted and reduced collagen bundles and abnormal lungs with impaired pulmonary surfactant clearance and reduced resistance to microbial pathogens in the lung. Features of the latter pathology resemble the human disorder pulmonary alveolar proteinosis (PAP). GM-CSF does not seem to be essential for the maintenance of normal levels of the major types of mature hematopoietic cells and their precursors in blood, marrow, and spleen. However, they implicate GM-CSF as being essential for normal vascular development, pulmonary physiology, and for resistance to local infection (Stanley et al., 1994; Dranoff et al., 1994; Plenz et al., 2003; Shibata et al., 2001). Recently, a strong association of auto-antibodies to GM-CSF with PAP has additionally implicated GM-CSF signaling abnormalities in the pathogenesis of PAP in humans. Together, these observations demonstrate that GM-CSF has a critical role in regulation of surfactant homeostasis and alveolar macrophage innate immune functions in the lung (Bonfield et al., 2002; Trapnell and Whitsett, 2002; Uchida et al., 2004; Kitamura et al., 1999).
High titers of autoantibodies with blocking activity to GM-CSF have been described in patients with myasthenia gravis. These patients did not show any other autoimmune phenomena or hemopoietic deficiencies or "other obvious clinical correlates" (Meager et al., 1999).
The compound E21R, a modified form of GM-CSF that antagonizes the function of GM-CSF, had been evaluated in a phase I safety trial and was found to have a good safety profile in cancer patients (Olver et al., 2002).
Thus, apart from the lung function, which should be monitored closely, other side effects are not expected when applying an anti-GM-CSF therapy.
So far, only antibodies derived from non-human species with GM-CSF neutralizing function have been generated. For example, EP 0499161 Al describes an antibody gener- ated by immunization of mice with oligopeptides, the sequence of which is derived from a GM-CSF. Furthermore, the application discloses a method of alleviating in a mammal in need thereof an undesirable effect of GM-CSF, which comprises administering to said mammal a GM-CSF-inhibiting amount of an immunoglobulin. However, that antibody is a murine antibody, rendering it unsuitable for human administration. Additionally, WO 03/068920 discloses an inhibitory chimeric mouse/human IgGl antibody. Antibodies that contain non-human sequences are likely to elicit an immune response in the human patient and are not appropriate for the therapeutic administration. For instance, in diseases where long-term treatment is required (e.g. chronic inflammatory diseases like rheumatoid arthritis, asthma and multiple sclerosis), continued administra- tion of a non-human therapeutic agent increases the likelihood of a severe inflammatory reaction and the production of human antibodies that may neutralize the therapeutic agent. Correspondingly, in light of the great potential for anti-GM-CSF antibody therapy, there is a high need for human anti-GM-CSF antibodies with high affinity that effectively block the GM-CSF/GM-CSF receptor interaction. Additionally, it would be advantageous to have one or more antibodies that can cross-react with GM-CSF of one or more non- human species in order to test their efficacy in animal-based in vivo models.
The present invention satisfies these and other needs by providing fully highly efficacious anti-GM-CSF antibodies, which are described below.
SUMMARY OF THE INVENTION
It is an object of the invention to provide human and humanized antibodies that can effectively block the GM-CSF/GM-CSF receptor interaction.
It is another object of the invention to provide antibodies that are safe for human administration.
It is also an object of the present invention to provide methods for treating disease or and/or conditions associated with the presence of GM-CSF by using one or more antibodies of the invention. These and other objects of the invention are more fully described herein. In one aspect, the invention provides an antigen-binding region that is specific for human GM-CSF, where the isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2xlO5 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of the human GM-CSF recep- tor alpha chain expressed on the CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x105 CHO-GMRa#l l cells, and (b) the concentration of the isolated human or humanized antibody or functional fragment thereof is about 5μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibody BVD2- 21Cl 1 and/or reference antibody MAB215. As used herein, a "TF-I proliferation assay" is defined as the assay essentially as described in Example 5B. The skilled worker can obtain CHO-Kl cells expressing human GM-CSF receptor alpha chain at a concentration similar to that which is expressed on about 2x105 CH0-GMRa#l 1 cells by following the teachings provided herein. The invention additionally provides an isolated human or humanized antibody or functional antibody fragment that contains an antigen-binding region as disclosed herein. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains an H-CDR3 region depicted in SEQ ID NO: 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; the antigen-binding region may further include an H-CDR2 re- gion depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; and the antigen-binding region also may contain an H-CDRl region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains a variable heavy chain depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Such a GM-CSF-specific antibody of the invention may contain an antigen-binding re- gion that contains an L-CDR3 region depicted in SEQ ID NO: 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; the antigen-binding region may further include an L-CDR2 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and the antigen-binding region also may contain an L-CDRl region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains a variable light chain depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
Peptide variants of the sequences disclosed herein are also embraced by the present invention. Accordingly, the invention includes anti-GM-CSF antibodies having a heavy chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Further included are anti-GM-CSF antibodies having a light chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
An antibody of the invention may be an IgG (e.g., IgGi), while an antibody fragment may be a Fab or scFv, for example. An inventive antibody fragment, accordingly, may be, or may contain, an antigen-binding region that behaves in one or more ways as described herein.
The invention also is related to isolated nucleic acid sequences, each of which can encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for GM-CSF. Such a nucleic acid sequence may encode a variable heavy chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, or a nu- cleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48. The nucleic acid might encode a variable light chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57, or a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57.
The nucleic acid sequence might encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for human GM- CSF, where the antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on 2x10s CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM-CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on 2x105 CHO-GMRa#l 1 cells and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5μg/ml, and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than the reference antibody BVD2-21C11 and/or reference antibody MAB215.
Nucleic acids of the invention are suitable for recombinant production. Thus, the invention also relates to vectors and host cells containing a nucleic acid sequence of the invention. Such host cells might be bacterial or eukaryotic cells.
Compositions of the invention may be used for therapeutic or prophylactic applications. The invention, therefore, includes a pharmaceutical composition containing an inventive antibody (or functional antibody fragment) and a pharmaceutically acceptable carrier or excipient therefor. In a related aspect, the invention provides a method for treating a disorder or condition associated with the undesired presence of GM-CSF or GM-CSF expressing cells. Such method contains the steps of administering to a subject in need thereof an effective amount of the pharmaceutical composition that contains an inventive antibody as described or contemplated herein. Such a disorder or condition might be an inflammatory disease, such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis and shock. Human or humanized antibodies (and functional fragments thereof) of the present invention may be cross-reactive with rat and/or rhesus (macaca) GM-CSF, as determined by solution equilibrium titration (SET), and/or TFl proliferation assay.
BRIEF DESCRIPTION OF THE FIGURES
Figure Ia provides nucleic acid sequences of various novel antibody variable heavy chain regions.
Figure Ib provides amino acid sequences of various novel antibody variable heavy chain regions. CDR regions HCDRl, HCDR2 and HCDR3 are designated from N- to C- terminus in boldface.
Figure 2a provides nucleic acid sequences of various novel antibody variable light chain regions.
Figure 2b provides amino acid sequences of various novel antibody variable light chain regions. CDR regions LCDRl, LCDR2 and LCDR3 are designated from N- to C- terminus in boldface.
Figure 3 provides amino acid sequences of variable heavy chain regions of consensus-based HuC AL® antibody master gene sequences. CDR regions HCDRl, HCDR2 and HCDR3 are designated from N- to C-terminus in boldface (SEQ ID NO: 41). Figure 4 provides amino acid sequences of variable light chain regions of consen: sus-based HuCAL® antibody master gene sequences. CDR regions LCDRl , LCDR2 and LCDR3 are designated from N- to C-terminus in boldface (SEQ ID NO: 42).
Figure 5 provides an example of a DNA sequence of pMORPH®X9_MOR03929_FH expression vector (SEQ ID NO: 43). Figure 6 provides expression level of GM-CSF receptor alpha, as determined by
FACS analysis using the GM-CSF receptor alpha specific antibody MAB 1006. CHO- GMRa#l 1 (solid line) is shown in comparison to CHO-Kl (dotted line). The x-axis represents the relative fluorescence value (RFL), measured in FL2 channel; the y-axis represents cell count. DETAILED DESCRIPTION OF THE INVENTION
The present invention is based on the discovery of novel antibodies that are specific to or have a high affinity for GM-CSF and possess one or more other novel properties.
Preferably, an antibody of the invention can deliver a therapeutic benefit to a subject. The antibodies of the invention, which may be human or humanized, can be used in many contexts, which are more fully described herein.
A "human" antibody or functional human antibody fragment is hereby defined as one that is not chimeric (e.g., not "humanized") and not from (either in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A "synthetic human antibody" is defined herein as an antibody having a sequence derived, in whole or in part, in silico from synthetic sequences that are based on the analysis of known human antibody sequences. In silico design of a human antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (i.e., such library being based on antibodies taken from a human natural source).
A "humanized antibody" or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frame- works of the variable domain are of human origin and the constant domain (if any) is of human origin.
As used herein, an antibody "binds specifically to," is "specific to/for" or "specifically recognizes" an antigen (here, GM-CSF) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. In its most general form (and when no defined reference is mentioned), "specific binding" is referring to the ability of the antibody to dis- criminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-,ECL-, IRMA-tests and peptide scans. For example, a standard ELISA assay can be carried out. The scoring may be carried out by standard color development {e.g. secondary antibody with horseradish peroxide and tet- ramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. This means the difference positive/negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like.
However, "specific binding" also may refer to the ability of an antibody to discriminate between the target antigen and one or more closely related antigen(s), which are used as reference points, e.g. between GM-CSF and IL3, IL5, IL-4, IL13 or M-CSF. Addition- ally, "specific binding" may relate to the ability of an antibody to discriminate between different parts of its target antigen, e.g. different domains or regions of GM-CSF, or between one or more key amino acid residues or stretches of amino acid residues of GM- CSF.
Also, as used herein, an "immunoglobulin" (Ig) hereby is defined as a protein be- longing to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A "functional fragment" of an antibody/immunoglobulin hereby is defined as a fragment of an anti- body/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region. An "antigen-binding region" of an antibody typically is found in one or more hypervariable region(s) of an antibody, i.e., the CDR-I, -2, and/or -3 regions; however, the variable "framework" regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs. Preferably, the "antigen-binding region" comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320). A preferred class of immunoglobulins for use in the present invention is IgG. "Functional fragments" of the invention include the domain of a F(ab')2 fragment, a Fab fragment, scFv or constructs comprising single immunoglobulin variable domains or single domain antibody polypeptides, e.g. single heavy chain variable domains or single light chain variable domains. The F(ab')2 or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the CHI and CL domains.
An antibody of the invention may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed in silico and encoded by nucleic acids that are synthetically created. In silico design of an antibody sequence is achieved, for example, by analyzing a database of human sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining in silico-cτeated sequences are described, for example, in Knappik et αl., J. MoI. Biol. (2000) 296:57; Krebs et αl., J. Immunol. Methods. (2001) 254:67; and U.S. Patent No. 6,300,064 issued to Knappik et αl., which hereby are incorporated by reference in their entirety.
Antibodies of the Invention
Throughout this document, reference is made to the following representative antibodies of the invention: "antibody nos." or "MOR" 03684, 04251, 03929, 04252, 04287, 04290, 04302, 04350, 04354, 04357, 03682, 04283, 04297 and 04342. MOR03684 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 1 (DNA)/SEQ ID NO: 1 1 (protein) and a variable light region corresponding to SEQ ID NO: 21 (DNA)/SEQ ID NO: 31 (protein). MOR04251 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 2 (DNA)/SEQ ID NO: 12 (protein) and a variable light region corresponding to SEQ ID NO: 22 (DNA)/SEQ ID NO: 32 (protein). MOR03929 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 3 (DNA)/SEQ ID NO: 13 (protein) and a variable light region corresponding to SEQ ID NO: 23 (DNA)/SEQ ID NO: 33 (protein). MOR04252 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 4 (DNA)/SEQ ID NO: 14 (protein) and a variable light region corresponding to SEQ ID NO: 24 (DNA)/SEQ ID NO: 34 (protein). MOR04287 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 5 (DNA)/SEQ ID NO: 15 (protein) and a variable light region corresponding to SEQ ID NO: 25 (DNA)/SEQ ID NO: 35 (protein). MOR04290 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 6 (DNA)/SEQ ID NO: 16 (protein) and a variable light region corresponding to SEQ ID NO: 26 (DNA)/SEQ ID NO: 36 (protein). MOR04302 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 7 (DNA)/SEQ ID NO: 17 (protein) and a variable light region corresponding to SEQ ID NO: 27 (DNA)/SEQ ID NO: 37 (protein). MOR04350 represents an antibody having a variable heavy region cor- responding to SEQ ID NO: 8 (DNA)/SEQ ID NO: 18 (protein) and a variable light region corresponding to SEQ ID NO: 28 (DNA)/SEQ ID NO: 38 (protein). MOR04354 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 9 (DNA)/SEQ ID NO: 19 (protein) and a variable light region corresponding to SEQ ID NO: 29 (DNA)/SEQ ID NO: 39 (protein). MOR04357 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 10 or 48 (DNA)/SEQ ID NO: 20 (protein) and a variable light region corresponding to SEQ ID NO: 30 or 57 (DNA)/SEQ ID NO: 40 (protein). MOR03682 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 44 (DNA)/SEQ ID NO: 49 (protein) and a variable light region corresponding to SEQ ID NO: 53 (DNA)/SEQ ID NO: 58 (protein). MOR04283 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 45 (DNA)/SEQ ID NO: 50 (protein) and a variable light region corresponding to SEQ ID NO: 54 (DNA)/SEQ ID NO: 59 (protein). MOR04297 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 46 (DNA)/SEQ ID NO: 51 (protein) and a variable light region corresponding to SEQ ID NO: 55 (DNA)/SEQ ID NO: 60 (protein). MOR04342 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 47 (DNA)/SEQ ID NO: 52 (protein) and a variable light region corresponding to SEQ ID NO: 56 (DNA)/SEQ ID NO: 61 (protein).
In one aspect, the invention provides antibodies having an antigen-binding region that can bind specifically to or has a high affinity for GM-CSF. An antibody is said to have a "high affinity" for an antigen if the affinity measurement is at least 100 nM
(monovalent affinity of Fab fragment). An inventive antibody or antigen-binding region preferably can bind to GM-CSF with an affinity of about less than 100 nM, more preferably less than about 60 nM, and still more preferably less than about 30 nM. Further preferred are antibodies that bind to GM-CSF with an affinity of less than about 10 nM, and more preferably less than about 3 nM. For instance, the affinity of an antibody of the invention against GM-CSF may be about 10.0 nM or 1 pM (monovalent affinity of Fab fragment).
Table 1 provides a summary of affinities of representative antibodies of the invention, as determined by surface plasmon resonance (Biacore) and Solution Equilibrium Titration (SET) analysis:
Table 1: Antibody Affinities
Biacore SET
MORO KD (pM) KD (pM)
3684 6420 16000
4251 70 7.4
3929 4260 2000
4302 174 63.5
4287 nd 17.9
4252 55 6
4290 122 11.1
4350 19 1.1
4354 21 2.8
4357 7 0.4
3682 nd 11406
4283 nd 113
4297 nd 49.2
4342 nd 4.9
nd": not determined
With reference to Table 1 , the affinity of MOR03684, 04251 , 03929, 04252, 04357,
04290, 04302, 04350 and 04354 was measured by surface plasmon resonance (Biacore) on immobilized recombinant GM-CSF. The Fab format of MOR03684, 04251, 03929, 04252, 04357, 04290, 04302, 04350 and 04354 exhibit a monovalent affinity range between about 6420 and 7 pM. The Fab format was also used for the determination of the affinities by solution equilibrium titration (SET). The right column of Table 1 denotes the binding strength of between about 16000 and 0.4 pM of the MORs in this method.
An antibody of the invention preferably is species cross-reactive with humans and at least one other species, which may be a rodent species or a non-human primate. The non- human primate can be rhesus. The rodent species can be rat. An antibody that is cross reactive with at least one rodent species, for example, can provide greater flexibility and benefits over known anti-GM-CSF antibodies, for purposes of conducting in vivo studies in multiple species with the same antibody.
Preferably, an antibody of the invention not only is able to bind to GM-CSF, but also is able to block the interaction of human GM-CSF with the alpha chain of human GM-CSF receptor expressed on CHO-Kl cells by at least 25%, preferably by at least 50%, more preferably by at least 60%, more preferably by at least 70%, preferably by at least 85% and most preferably by at least 100%. In a preferred embodiment, an antibody of the invention is able to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x105 CHO-Kl cells by at least 50% under the following conditions: the concentration of the human GM-CSF receptor alpha chain expressed on the CHO-Kl cells is similar to the concentration of human GM- CSF receptor alpha chain expressed on about 2x105 CHO-GMRa#l 1 cells, and the concentration of the inventive antibody is about 5μg/ml. In this regard, the skilled worker can obtain CHO-Kl cells expressing human GM-
CSF receptor alpha at a concentration similar to that which is expressed on about 2x105 CHO-GMRa#l l cells by, e.g., by transfecting a population of CHO-Kl cells with a suitable expression vector encoding GM-CSF receptor alpha to generate different stable cell lines expressing defined levels GM-CSF receptor alpha; then, the stable cell lines are analyzed in FACS analysis to determine GM-CSF receptor alpha expression levels according to the protocol essentially as described in Example 3C; a cell line that expresses human GM-CSF receptor alpha at a concentration similar to that which is expressed on about 2x105 CHO-GMRa#l l cells is identified by comparing the median fluorescence value (MFL) of such transfected cells to the MFL value set forth in Example 3C. As used herein, a cell line is defined as expressing GM-CSF receptor alpha at a concentration "similar" to that which is expressed on about 2x10s CHO-GMRa#l l cells" if the MFL value of the transfected cell line does not deviate by more than a two-fold factor from the MFL value for the CHO-GMRa#l 1 cell as set forth in Example 3C.
Furthermore, an antibody of the invention is able to neutralize human GM-CSF in a TF-I proliferation assay with a lower IC50 value than the reference antibody BVD2- 21Cl 1 and/or MAB215, preferably an at least five-fold lower IC50 value, more preferably with an at least 10-fold lower IC50 value than the reference antibody BVD2-21C1 1 and/or MAB215, more preferably with an at least 15-fold lower IC50 value than the reference antibody BVD2-21C1 1 and/or MAB215, more preferably with an at least 20-fold lower IC50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 30-fold lower IC50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 50-fold lower IC50 value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 100-fold lower IC50 value than the reference antibody BVD2-21C11 and/or MAB215 and most preferably with an at least 120-fold lower IC50 value than the reference antibody BVD2-21C11 and/or MAB215.
Peptide Variants
Antibodies of the invention are not limited to the specific peptide sequences provided herein. Rather, the invention also embodies variants of these polypeptides. With reference to the instant disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while appreciating that variants having the ability to block the interaction of GM-CSF to the alpha chain of the GM-CSF receptor fall within the scope of the present invention. As used in this context, "ability to block the interaction of GM- CSF to the alpha chain of the GM-CSF receptor" means a functional characteristic ascribed to an anti-GM-CSF antibody of the invention.
A variant can include, for example, an antibody that has at least one altered complementarity determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-a-vis a peptide sequence disclosed herein. To better illustrate this concept, a brief description of antibody structure follows.
An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs. The antigen- binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and can also play an important role in antigen binding. By al- tering one or more amino acid residues in a CDR or FR region, the skilled worker routinely can generate mutated or diversified antibody sequences, which can be screened against the antigen, for new or improved properties, for example.
Tables 2a (VH) and 2b (VL) delineate the CDR and FR regions for certain antibodies of the invention and compare amino acids at a given position to each other and to corresponding consensus or "master gene" sequences (as described in U.S. Patent No. 6,300,064):
Table 2a: VH Sequences
Figure imgf000022_0001
Table 2a continued:
Figure imgf000023_0001
Table 2b: VL Sequences
Figure imgf000024_0001
Table 2b continued:
Figure imgf000025_0001
The original HuCAL® master genes have been constructed with their authentic N-termini, e.g. VL lambda 3 contains the amino acids "SY" at position 1 and 2; and VH3 contains the amino acid "E" at position 1. During construction of the HuCAL® Fab libraries, including the HuCAL GOLD® library, the first two amino acids have been changed to "DI" in the VL lambda 3 chain; and the first amino acid has been changed to "Q" in the VH3 chain.
The skilled worker can use the data in Tables 2a and 2b to design peptide variants that are within the scope of the present invention. It is preferred that variants are constructed by changing amino acids within one or more CDR regions; a variant might also have one or more altered framework regions. With reference to a comparison of the novel antibodies to each other, candidate residues that can be changed include e.g. residues 27 or 51 of the variable light and e.g. residues 32 or 56 of the variable heavy chains of MOR04251, since these are positions of variance vis-a-vis each other. Alterations also may be made in the framework regions. For example, a peptide FR domain might be altered where there is a deviation in a residue compared to a germline sequence.
With reference to a comparison of the novel antibodies to the corresponding consensus or "master gene" sequence, candidate residues that can be changed include e.g. residues 27, 50 or 90 of the variable light chain of MOR04251 compared to VLλ3 and e.g. residues 33, 52 or 96 of the variable heavy chain of MOR04251 compared to VH3. Alternatively, the skilled worker could make the same analysis by comparing the amino acid sequences disclosed herein to known sequences of the same class of such antibodies, using, for example, the procedure described by Knappik et al. (2000), and U.S. Patent No. 6,300,064 issued to Knappik et al.
Furthermore, variants may be obtained by using one MOR as starting point for optimiza- tion by diversifying one or more amino acid residues in the MOR, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants for variants with improved properties. Particularly preferred is diversification of one or more amino acid residues in CDR-3 of VL, CDR-3 of VH, CDR-I of VL and/or CDR- 2 of VH. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekas et al., 1994). Conservative Amino Acid Variants
Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, i.e., "conservative substitutions," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
For example, (a) nonpolar (hydrophobic) amino acids include alanine, leucine, iso- leucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and gluta- mine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their ability to disrupt α-helices. Simi- larly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in α-helices, while valine, iso- leucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in β-pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. Some preferred substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants.
As used herein, "sequence identity" between two polypeptide sequences, indicates the percentage of amino acids that are identical between the sequences. "Sequence ho- mology", indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. Preferred polypeptide sequences of the invention have a sequence identity in the CDR regions of at least 60%, more preferably, at least 70% or 80%, still more preferably at least 90% and most preferably at least 95%. Preferred antibodies also have a sequence homology in the CDR regions of at least 80%, more preferably 90% and most preferably 95%. DNA molecules of the invention
The present invention also relates to the DNA molecules that encode an antibody of the invention. These sequences include, but are not limited to, those DNA molecules set forth in Figures 1 a and 2a. DNA molecules of the invention are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants within the invention may be described by reference to their physical properties in hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is double stranded, its equivalent or homolog, using nucleic acid hybridization techniques. It also will be recog- nized that hybridization can occur with less than 100% complementarity. However, given appropriate choice of conditions, hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe. For guidance regarding such conditions see, Sambrook et al., 1989 (Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA) and Ausubel et al., 1995 (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G., Smith, J. A., & Struhl, K. eds. (1995). Current Protocols in Molecular Biology. New York: John Wiley and Sons).
Structural similarity between two polynucleotide sequences can be expressed as a function of "stringency" of the conditions under which the two sequences will hybridize with one another. As used herein, the term "stringency" refers to the extent that the conditions disfavor hybridization. Stringent conditions strongly disfavor hybridization, and only the most structurally related molecules will hybridize to one another under such conditions. Conversely, non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness. Hybridization stringency, therefore, directly cor- relates with the structural relationships of two nucleic acid sequences. The following relationships are useful in correlating hybridization and relatedness (where Tm is the melting temperature of a nucleic acid duplex): a. Tm = 69.3 + 0.41(G+C)%
b. The Tn, of a duplex DNA decreases by 10C with every increase of
1% in the number of mismatched base pairs. c. (Tm)μ2 - (T01) μ, = 18.5 logi0μ2/μl where μl and μ2 are the ionic strengths of two solutions.
Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the "binding" phase and the "washing" phase.
First, in the binding phase, the probe is bound to the target under conditions favoring hybridization. Stringency is usually controlled at this stage by altering the temperature. For high stringency, the temperature is usually between 650C and 70°C, unless short (< 20 nt) oligonucleotide probes are used. A representative hybridization solution com- prises 6X SSC, 0.5% SDS, 5X Denhardt's solution and 100 μg of nonspecific carrier DNA. See Ausubel et al, section 2.9, supplement 27 (1994). Of course, many different, yet functionally equivalent, buffer conditions are known. Where the degree of relatedness is lower, a lower temperature may be chosen. Low stringency binding temperatures are between about 250C and 4O0C. Medium stringency is between at least about 4O0C to less than about 65°C. High stringency is at least about 650C.
Second, the excess probe is removed by washing. It is at this phase that more stringent conditions usually are applied. Hence, it is this "washing" stage that is most important in determining relatedness via hybridization. Washing solutions typically contain lower salt concentrations. One exemplary medium stringency solution contains 2X SSC and 0.1% SDS. A high stringency wash solution contains the equivalent (in ionic strength) of less than about 0.2X SSC, with a preferred stringent solution containing about 0.1 X SSC. The temperatures associated with various stringencies are the same as discussed above for "binding." The washing solution also typically is replaced a number of times during washing. For example, typical high stringency washing conditions comprise washing twice for 30 minutes at 55° C and three times for 15 minutes at 60° C. Accordingly, the present invention includes nucleic acid molecules that hybridize to the molecules of set forth in Figures Ia and 2a under high stringency binding and washing conditions, where such nucleic molecules encode an antibody or functional fragment thereof having properties as described herein. Preferred molecules (from an mRNA perspective) are those that have at least 75% or 80% (preferably at least 85%, more preferably at least 90% and most preferably at least 95%) homology or sequence identity with one of the DNA molecules described herein.
Functionally Equivalent Variants
It is recognized that variants of DNA molecules provided herein can be constructed in several different ways. For example, they may be constructed as completely synthetic DNAs. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel et al, section 2.11, Supplement 21 (1993). Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana et al, J. MoI. Biol. 72:209-217 (1971); see also Ausubel et al, supra, Section 8.2. Synthetic DNAs preferably are designed with convenient restriction sites engineered at the 5' and 3' ends of the gene to facilitate cloning into an appropriate vector.
As indicated, a method of generating variants is to start with one of the DNAs dis- closed herein and then to conduct site-directed mutagenesis. See Ausubel et al., supra, chapter 8, Supplement 37 (1997). In a typical method, a target DNA is cloned into a single-stranded DNA bacteriophage vehicle. Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alter ation(s). The complementary strand is synthesized and the double stranded phage is introduced into a host. Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing. In addition, various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants. Recombinant DNA constructs and expression
The present invention further provides recombinant DNA constructs comprising one or more of the nucleotide sequences of the present invention. The recombinant constructs of the present invention are used in connection with a vector, such as a plasmid, phagemid, phage or viral vector, into which a DNA molecule encoding an antibody of the invention is inserted.
The encoded gene may be produced by techniques described in Sambrook et al., 1989, and Ausubel et al, 1989. Alternatively, the DNA sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in OLIGONUCLEOTIDE SYNTHESIS (1984, Gait, ed., IRL Press, Oxford), which is incorporated by reference herein in its entirety. Recombinant constructs of the invention are comprised with expression vectors that are capable of expressing the RNA and/or protein products of the encoded DNA(s). The vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF). The vector may further comprise a selectable marker sequence. Specific initiation and bacterial secretory signals also may be required for efficient translation of inserted target gene coding sequences.
The present invention further provides host cells containing at least one of the DNAs of the present invention. The host cell can be virtually any cell for which expres- sion vectors are available. It may be, for example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell or a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, elec- troporation or phage infection.
Bacterial Expression
Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus.
Bacterial vectors may be, for example, bacteriophage-, plasmid- or phagemid-based. These vectors can contain a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017). Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is de-repressed/induced by appropriate means {e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifu- gation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
Therapeutic Methods
Therapeutic methods involve administering to a subject in need of treatment a therapeutically effective amount of an antibody contemplated by the invention. A "therapeutically effective" amount hereby is defined as the amount of an antibody that is of suf- ficient quantity to effectively block the interaction between GM-CSF and its receptor in a treated area of a subject — either as a single dose or according to a multiple dose regimen, alone or in combination with other agents, which leads to the alleviation of an adverse condition, yet which amount is toxicologically tolerable. The subject may be a human or non-human animal {e.g., rat or rhesus). An antibody of the invention might be co-administered with known medicaments, and in some instances the antibody might itself be modified. For example, an antibody could be conjugated to an immunotoxin or radioisotope to potentially further increase efficacy. The inventive antibodies can be used as a therapeutic or a diagnostic tool in a variety of situations where GM-CSF is undesirably expressed or found. Disorders and conditions particularly suitable for treatment with an antibody of the inventions are inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis or shock. To treat any of the foregoing disorders, pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. An antibody of the invention can be administered by any suitable means, which can vary, depending on the type of disorder being treated. Possible administration routes include parenteral (e.g., intramus- cular, intravenous, intraarterial, intraperitoneal, or subcutaneous), intrapulmonary and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration. In addition, an antibody of the invention might be administered by pulse infusion, with, e.g., declining doses of the antibody. Preferably, the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. The amount to be administered will depend on a variety of factors such as the clinical symptoms, weight of the individual, whether other drugs are administered. The skilled artisan will recognize that the route of administration will vary depending on the disorder or condition to be treated.
Determining a therapeutically effective amount of the novel polypeptide, according to this invention, largely will depend on particular patient characteristics, route of administration, and the nature of the disorder being treated. General guidance can be found, for example, in the publications of the International Conference on Harmonisation and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, pp. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). More specifically, deter- mining a therapeutically effective amount will depend on such factors as toxicity and efficacy of the medicament. Toxicity may be determined using methods well known in the art and found in the foregoing references. Efficacy may be determined utilizing the same guidance in conjunction with the methods described below in the Examples.
Diagnostic Methods
GM-CSF is expressed by various cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells; thus, an anti-GM-CSF antibody of the invention may be employed in order to image or visualize a site of possible accumulation of GM-CSF in different tissues in a patient. In this regard, an antibody can be de- tectably labeled, through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.) fluorescent labels, paramagnetic atoms, etc. Procedures for accomplishing such labeling are well known to the art. Clinical application of antibodies in diagnostic imaging are reviewed by Grossman, H. B., Urol. Clin. North Amer. 13:465-474 (1986)), Unger, E. C. et al., Invest. Radiol. 20:693-700 (1985)), and Khaw, B. A. et al., Science 209:295-297 (1980)). The detection of foci of such detectably labeled antibodies might be indicative of a site of inflammation, for example. In one embodiment, this examination is done by removing samples of tissue or blood and incubating such samples in the presence of the detectably labeled antibodies. In a preferred embodiment, this technique is done in a noninvasive manner through the use of magnetic imaging, fluorography, etc. Such a diagnos- tic test may be employed in monitoring the success of treatment of diseases, where presence or absence of GM-CSF is a relevant indicator. The invention also contemplates the use of an anti- GM-CSF antibody, as described herein for diagnostics in an ex vivo setting.
Therapeutic And Diagnostic Compositions
The antibodies of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, wherein an antibody of the invention (including any functional fragment thereof) is combined in a mixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of one or more of the antibodies of the present invention, to- gether with a suitable amount of carrier vehicle.
Preparations may be suitably formulated to give controlled-release of the active compound. Controlled-release preparations may be achieved through the use of polymers to complex or absorb anti- GM-CSF antibody. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, poly- vinyl, pyrrolidone, ethylenevinyl-acetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate anti-GM-CSF antibody into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery sys- terns, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).
The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules, or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
The invention further is understood by reference to the following working examples, which are intended to illustrate and, hence, not limit the invention.
EXAMPLES
Example 1: Generation of human GM-CSF specific antibodies from the HuCAL GOLD® Library
A. Phagemid rescue, phage amplification and purification
HuCAL GOLD® library was amplified in 2xYT medium containing 34 μg/ml chloramphenicol and 1 % glucose (2x YT-CG). After helper phage infection (VCSM 13) at an OD6O0 of 0.5 (30 min at 37°C without shaking; 30 min at 370C shaking at 250 rpm), cells were spun down (4120 g; 5 min; 4°C), resuspended in 2xYT / 34 μg/ml chloramphenicol / 50 μg/ml kanamycin / 0.25mM IPTG and grown overnight at 220C. Phages were PEG- precipitated from the supernatant, resuspended in PBS / 20 % glycerol and stored at -8O0C. Phage amplification between two panning rounds was conducted as follows: mid- log phase E. coli TGl cells were infected with eluted phages and plated onto LB-agar supplemented with 1 % of glucose and 34 μg/ml of chloramphenicol. After overnight incubation at 3O0C, colonies were scraped off and used to inoculate 2x YT-CG until an ODόoonm of 0.5 was reached and helper phage added as described above.
B. Pannings with HuCAL GOLD® For the selection of antibodies recognizing human GM-CSF several panning strategies were applied. In summary, HuCAL GOLD® antibody-phages were divided into three pools comprising different VH master genes. These pools were individually subjected to either a) a solid phase panning on biotinylated human GM-CSF protein (custom made by R&D Systems, Minneapolis, MN) directly coated on neutravidin coated 96well plates (Pierce, Rockford, IL) as solid support for three rounds or b) a solution panning on biotinylated human GM-CSF protein captured onto streptavidin coated Dynabeads (Dynal, Oslo, Norway) for three rounds.
In detail, for panning on immobilized biotinylated GM-CSF, wells of the neutravidin plate were washed three times with 300 μl PBS. The antigen was diluted to a concentra- tion of 3 μg/ml (200 nM) in PBS and 0.1 ml was coated per well for 2h at room temperature. After two washing steps with 300 μl PBS the wells were incubated with blocking buffer containing 2x Chemiblocker (Chemicon, Temecula, CA) diluted 1:1 in PBS.
Prior to the selections, 100 μl of HuCAL GOLD® phages were pre-adsorbed in lOOμl blocking buffer containing 0.4μl 25% Tween20 for 0.5 h at RT. Blocked phages were transferred in lOOμl aliquots to wells of a neutravidin plate for 0.5 h at RT. This step was repeated twice for pre-absorption.
After washing (2x 300μl PBS) of the coated and blocked neutravidin microtiter plate, 0.1 ml of the pre-adsorbed phages were added to the coated wells and incubated for 1.5 h at RT shaking gently. This incubation was followed by 10 wash cycles with PBS / 0.05% Tween20 at RT.
Bound phages were eluted by adding 120μl of 20 mM DTT in 10 mM Tris pH 8.0 per well for 10 min at RT. The eluate was removed and added to 14 ml E. coli TGl grown to an ODδoonm of 0.6-0.8. Wells were additionally washed with 200μl PBS and this solution was also added to the TGl cells. Phage infection of E. coli was allowed for 45 min at 370C without shaking. Additionally, 200 μl of TGl cells grown to an OD60onm of 0.6-0.8 were added to the selection wells for 45 minutes at 370C without shaking. These TG-I cells were added to the 14ml culture already containing the phages from the first elution step. After centrifugation for 10 min at 5000rpm, the bacterial pellets were each resus- pended in 500μl 2xYT medium, plated on 2x YT-CG agar plates and incubated overnight at 3O0C. Colonies were then scraped from the plates and phages were rescued and amplified as described above.
The second and third rounds of selection were performed in an identical way to the first round of selection with the only difference that the washing conditions after binding of phage were more stringent. Additionally, in the third round of selection, phages were submitted to an additional preadsorption step on streptavidin-coated beads (Dynabeads M-280; Dynal). Eppendorf tubes were blocked with Chemiblocker solution by incubation for 30 min at RT. Of each phage pool 0.3ml were mixed 1 : 1 with 2xChemiblocker solution containing 0.05% Tween20 and incubated for Ih at RT in the blocked Eppendorf tubes on a rotator. Blocked phages were then transferred to newly blocked Eppendorf tubes and 50μl of Dynabeads M-280 were added for another 30min for preadsorption. Beads were removed using a magnetic device (Dynal MPC-E). Aliquots of 150μl of phages were then transferred to neutravidin plates for further preadsorption as in round 1 and 2 (see above).
For the solution panning using biotinylated GM-CSF coupled to Dynabeads the following protocol was applied: 1.5 ml Eppendorf tubes were blocked with 1.5 ml 2xChemiblocker diluted 1 : 1 with PBS over night at 4°C. 200μl streptavidin coated magnetic beads (Dynabeads M-280; Dynal) were washed Ix with 200 μl PBS and resuspended in 200 μl lxChemiblocker (diluted in Ix PBS). Blocking of beads was performed in preblocked tubes over night at 4°C. Phages diluted in 500μl PBS for each panning condition were mixed with 500μl 2xChemiblocker / 0.1% Tween 1 h at RT (rotator). Preadsorption of phages was performed twice: 50 μl of blocked Streptavidin magnetic beads were added to the blocked phages and incubated for 30 min at RT on a rotator. After separation of beads via a magnetic device (Dynal MPC-E) the phage supernatant (~lml) was trans- ferred to a new blocked tube and preadsorption was repeated on 50 μl blocked beads for 30 min. Then, 200 nM biotinylated hGM-CSF was added to blocked phages in a new blocked 1.5 ml tube and incubated for 1 h at RT on a rotator. 100 μl of blocked streptavidin magnetic beads were added to each panning phage pool and incubated 10 min at RT on a rotator. Phage bound to biotinylated GM-CSF and therefore immobilized to the magnetic beads were collected with a magnetic particle separator (Dynal MPC-E). Beads were then washed 7x in PBS/0.05% Tween using a rotator, followed by washing another three times with PBS. Elution of phage from the Dynabeads was performed adding 300 μl 2OmM DTT in 1 OmM Tris/HCl pH8 to each tube for 10 min. Dynabeads were removed by the magnetic particle separator and the supernatant was added to 14ml of a E.coli TG-I culture grown to OD600nm of 0.6-0.8. Beads were then washed once with 200μl PBS and PBS containing additional removed phage was added to the 14 ml E.coli TG-I culture.
After centrifugation for 10 min at 5000rpm, the bacterial pellets were each resuspended in 500μl 2xYT medium, plated on 2x YT-CG agar plates and incubated overnight at 30°C. Colonies were then scraped from the plates and phages were rescued and amplified as described above. The second and third rounds of the solution panning on biotinylated GM-CSF was performed according to the protocol of the first round except for increasing the stringency of the washing procedure.
C. Subcloning of selected Fab fragments and expression of soluble Fab fragments
The Fab encoding inserts of the selected HuCAL GOLD® phagemids were subcloned into the expression vector pMORPH®X9_Fab_FH (Fig 5) to facilitate rapid expression of soluble Fab. The DNA of the selected clones was digested with Xbal and EcoKL, thereby cutting out the Fab encoding insert (ompA-VLCL and phoA-Fd), and cloned into the
Xba\ / EcoRΪ digested vector pM0RPH®X9 Fab_FH. Fabs expressed in these vectors carry two C-terminal tags (FLAG™ and 6xHis, respectively) for detection and purification.
D. Microexpression of HuCAL GOLD® Fab antibodies in E. coli
Single colonies obtained after subcloning into pMORPH®X9 Fab_FH were used to inoculate wells of a sterile 96-well microtiter plate containing 100 μl 2xTY/Cm/l% GIu medium per well and grown overnight at 370C. 5 μl of each TG-I E. coli culture was transferred to a new sterile 96-well microtiter plate containing 100 μl 2xTY/Cm/0.1% GIu medium per well. Microtiter plates were incubated at 3O0C shaking at 400 rpm on a mi- croplate shaker until the cultures were slightly turbid (-2-4 hrs) with an ODδoonm of 0.5.
To these expression plates, 20 μl 2xYT/Cm/ 3mM IPTG were added per well (end concentration 0.5 mM IPTG), sealed with a gas-permeable tape and incubated overnight at 300C shaking at 400 rpm. Generation of whole cell lvsates (BEL extracts)
To each well of the expression plates, 40 μl BEL buffer (2xBBS/EDTA: 24.7 g/1 boric acid, 18.7 g NaCl/1, 1.49 g EDTA/1, pH8) was added containing 2.5 mg/ml lysozyme and incubated for 1 h at 220C on a microtiter plate shaker (400 rpm). BEL extracts were used for binding analysis by ELISA or a BioVeris M-series® 384 analyzer (see Example 2). E. Expression of HuCAL® GOLD Fab antibodies in E. coli and purification
Expression of Fab fragments encoded by pMORPH®X9 Fab_FH in TG-I cells was carried out in shaker flask cultures with 1 1 of 2xYT medium supplemented with 34 μg/ml chloramphenicol. After induction with 0.5 mM IPTG, cells were grown at 22°C for 16 h. Whole cell extracts of cell pellets were prepared by French Press and Fab fragments isolated by nickel/NTA chromatography (Qiagen, Hilden, Germany). Concentrations were determined by UV-spectrophotometry (Krebs et al., 2001).
Example 2: Identification of hGM-CSF specific antibodies
BEL extracts of individual E. coli clones selected by the above mentioned panning strategies were analyzed by ELISA or BioVeris (BioVeris M-series® 384 analyzer) in order to identify clones encoding hGM-CSF specific Fabs.
A. Enzyme Linked Immunosorbent Assay (ELISA) Techniques
Human recombinant biotinylated GM-CSF (R&D Systems) was coated at 1.5 μg/ml in PBS onto Neutravidin microtiter plates for 2h at RT.
After coating of antigen the wells were blocked with PBS / 0.05 % Tween (PBS-T) with 1% BSA for 1 h at RT. After washing of the wells with PBS-T BEL-extract, purified Hu- CAL® Fab or control IgGs were diluted in PBS, added to the wells and incubated for 1 h at RT. For detection of the primary antibodies, the following secondary antibodies were applied: alkaline phospatase (AP)-conjugated AffiniPure F(ab')2 fragment, goat anti- human, -anti-mouse or -anti-rat IgG (Jackson Immuno Research). For the detection of AP-conjugates fluorogenic substrates like AttoPhos (Roche) were used according to the instructions by the manufacturer. Between all incubation steps, the wells of the microtiter plate were washed with PBS-T three times and three times after the final incubation with secondary antibody. Fluorescence was measured in a TECAN Spectrafluor plate reader. B. Electrochemiluminescene (BioVeris) based binding analysis for detection of GM-CSF binding Fab in lysates
Alternative to the ELISA experiments for the detection of GM-CSF binding Fab antibodies in E. coli lysates (BEL extracts), binding was analyzed in BioVeris M-SERIES® 384 AnalyzerBioVeris, Europe, Witney, Oxforfshire, UK).
To this end BEL extract was diluted at least 1 :50 and maximally 1 :1000 in assay buffer (PBS/0,05%Tween20/0.5%BSA) for use in BioVeris screening. Biotinylated GM-CSF (R&D Systems) was coupled to streptavidin coated paramagnetic beads, Dynabeads (Dy- nal), at a concentration of O.lμg/ml. Per well of a 96 or 384 well plate 25 or 15 μl of a 1:25 dilution of the Dynabead-stock solution was used. Beads were washed three times with assay buffer before adding biotinylated GM-CSF for 30 min at RT on a shaker. Beads were then washed three times with assay buffer and finally resuspended in fresh assay buffer . Anti-human (Fab) '2 (Dianova) was ruthenium labelled using the BV-tag™ (BioVeris Europe, Witney, Oxfordshire, UK). This secondary antibody was added to the GM-CSF coupled beads at a concentration of 6μg/ml immediately before use. lOOμl or 60μl of diluted BEL extract (see above) of E. coli expression cultures containing Fab antibodies was filled into wells of a 96 or 384 well plate and, respectively, 25 or 15μl of the GM-CSF coupled beads plus anti-Fab-BV-tag™ secondary antibody mix was added to each well and incubated for 2h at RT on a plate shaking device. The plates were analyzed in a BioVeris M-SERIES® 384 Analyzer.
After sequence analysis seventy-four (74) unique clones were identified that showed sufficiently strong binding (signal:noise ratio greater than 10:1 in ELISA or 50:1 in BioVeris). These clones were expressed, purified and were tested in functional assays.
C. Determination of the molecular specificity and species crossreactivity of selected anti-hGM-CSF Fabs.
Crossreactivity of the anti-hGM-CSF antibodies was determined to the following ana- lytes: rat and mouse GM-CSF, human IL-3, human IL-4, , human IL-5, , human IL-13, , human M-CSF (all from Peprotech, London, UK). This was performed in a capture set-up by surface plasmon resonance (Biacore 3000, Uppsala, Sweden).
CM5 chips (Biacore, Sweden) were coated with 5000-6000RU anti-F(ab)2 (Dianova, Af- finipure F(ab)2 Fragment Goat Anti-Human IgG, F(ab)2 Fragment specific); 80μg/ml 1OmM acetate buffer, pH4 on all 4 flow cells, using standard EDC-NHS amine coupling chemistry. On the flow cells 2-4 specific GM-CSF Fabs (20μl of 50OnM Fab at a flowrate of 5 μl/ml, 300-400RU) were captured. After capturing of the specific Fab, buffer was injected, to determine the dissociation of anti-Fab/Fab interaction. In a following cycle, the analyte growth factor was injected (20μl, flow rate 20μl/min) at a concentration range between 15 and 200OnM for the determination of the specific signal. Afterwards the achieved buffer sensogram was manually subtracted from the specific one. After each cycle, the flow cells were regenerated with 10OmM HCl (5μl).
Seven HuCAL® anti-tiGM-CSF antibodies including MOR03684 and MOR03682 were tested and were specific for human GM-CSF and did not bind to any of the other cytoki- nes or mouse or rat GM-CSF . In contrast Fab MOR03929 showed significant cross reactivity to rat GM-CSF.
Example 3: Identification of anti-human GM-CSF Fab candidates that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha
74 different hGM-CSF specific antibodies which were selected from the HuCAL GOLD® library were tested for the potency to inhibit the interaction between hGM-CSF and its receptor. The interaction was tested in two ways, (i) one being a proliferation assay using the GM-CSF dependent TF-I cell line (Kitamura et al., 1989) and (ii) the other being a FACS analysis with a recombinant CHO cell line expressing the alpha chain of the GM- CSF receptor. In the TF-I proliferation assay, the ability of the anti-GM-CSF antibodies to block the interaction of GM-CSF with the endogenous GM-CSF receptor consisting of the alpha and beta chain was analyzed leading to reduction in cell proliferation. In the FACS assay the specific inhibition of the interaction between GM-CSF and the alpha chain of the GM-CSF receptor was determined.
A. Cloning and expression of macaca mulatto and human GM-CSF Macaca mulatto GM-CSF full-length cDNA (GenBank accession no.: AY007376) was synthesized by gene synthesis (geneART GmbH, Regensburg, Germany) and cloned into the pCR-Script-Amp vector (Stratagene, LaJoIIa, CA, USA). Subsequently the cDNA was cloned into the eukaryotic expression vector pcDNA3.1 (+) (Invitrogen, Paisley, UK) yielding pcDNA-macGM-CSF. The cDNA of human GM-CSF (Genbank accession num- ber NP_000749 ) was cloned by RT-PCR technique from RNA isolated from 1x10e7 TF- 1 cells using the RNeasy kit from Qiagen (Hilden, Germany). Reverse transcription was performed with the SuperscriptII kit using random hexamers (Gibco) followed amplification of the GM-CSF cDNA by PCR. The obtained PCR-product was cloned into expression vector pcDNA3.1(+) yielding pcDNA-huGM-CSF. HEK293 cells were transiently transfected with these expression vectors respectively using lipofectamine (Stratagene, LaJoIIa, USA). The medium containing the secreted recombinant macaca or human GM-CSF was harvested 4 days after transfection.
B. Inhibition of GM-CSF dependent proliferation of TF-I cells by anti-hGM- CSF Fabs using human or macaca GM-CSF
TF-I (Kitamura et al., 1989) cells were grown according to the provider's protocol (DSMZ, Braunschweig, Germany; DSMZ No. ACC 334). TF-I cells were washed twice with RPMI 1640 medium (10% FCS) and then seeded at a concentration of 2 x 105 cells/ml in 50μl per well of a flat bottom 96well cell culture dish. Human recombinant GM-CSF ("Leucomax", ESSEX Pharma, Mϋnchen) at 0.5ng/ml and HuCAL® Fab antibodies (200ng/ml - 200 μg/ml diluted in RPMI 1640 medium, 10% FCS) were mixed for 30 min and 50μl of the mix was added to the TF-I cells, so that the final concentration of GM-CSF was 0.25ng/ml. Maximal cell proliferation (0% inhibition) was measured incubating TF-I cells at a final GM-CSF of concentration of 0.25ng/ml, without the addition of antibody. 100% inhibition of TF-I proliferation was measured by omitting GM-CSF from the assay and keeping the cells in RPMI 1640 medium (10% FCS) only. TFl cells were then incubated for 72 hours at 370C with 5% CO2 in a humidified chamber. Cell vitality was measured by adding MTT or XTT reagent (Roche, Mannheim, Germany) according to the manufacturer's recommendation. Overall 19 Fab were identified that showed significant inhibition of TF-I proliferation. The binders MOR03682, MOR03684 and MOR03929 showed consistent inhibition of TFl cell proliferation of greater than 50% at a concentration of 2μM. The inhibitory activity of these non-optimized Fabs was not strong enough to determine an IC50 dose, because full inhibition could not be achieved. In comparison, monoclonal antibodies BVD2-21C11 (BD Biosciences Pharm- ingen; Cat#554503) and MAB215 (R&D Systems; Cat#MAB215) were able to fully inhibit TF-I proliferation. Additionally, binding of MOR03682 and MOR03684 to native human GM-CSF was tested in the TF-I proliferation assay. Instead of adding purified human recombinant GM- CSF to the TF-I cells a supernatant of 5637 cells (DSMZ No. ACC 35) that secrete native human GM-CSF into the medium was used. From a dose response curve comparing the effect of recombinant human GM-CSF with different dilutions of the 5637 supernatant it was determined that the medium contained ~ 5 ng/ml of native human GM-CSF. By preincubation of the 5637 supernatant with anti-human GM-CSF Fab MOR03682 or MOR03684 the binding of native human GM-CSF to the TF-I cells was blocked so that the viability of cells was reduced comparably to the experiment with recombinant human GM-CSF. MOR03684 and MOR03682 thus binds to native human GM-CSF. Fab MOR03929 was not tested in this assay.
Additionally, the cross reactivity to macaca GM-CSF was tested in the TF-I proliferation assay. Instead of adding purified human GM-CSF to the TF-I cells a supernatant of trans- fected HEK293 cells that secrete recombinant macaca GM-CSF into the medium was used. TF-I cells proliferated in the presence of macaca GM-CSF containing supernatant but not in the presence of supernatant from untransfected HEK293 cells. From a dose response curve comparing the effect of recombinant human GM-CSF with different dilutions of the HEK-293 medium it was determined that the medium of the transfected cells contained ~2μg/ml macaca GM-CSF. By preincubation of the macaca GM-CSF supernatant with anti-human GM-CSF Fab MOR03682 or MOR03684 the binding of macaca GM-CSF to the TF-I cells was blocked so that the viability of cells was significantly reduced. MOR03682 and MOR03684_thus are cross-reactive with macaca GM-CSF. Fab MOR03929 was not tested in this assay.
C. Blocking of GM-CSF binding to the GM-CSF receptor alpha by anti-hGM-CSF Fabs
In order to test binding of GM-CSF to a cell surface expressed GM-CSF receptor alpha chain the cDNA was cloned into an expression vector and stably transfected into CHO- Kl cells (DSMZ ACC 110).
Cloning of a stable CHO-Kl cell line expressing the alpha chain of the GM-CSF receptor The cDNA of the human GM-CSF receptor alpha chain (Genbank accession number M64445) was cloned by RT-PCR technique from RNA isolated from Ixlθe7 TF-I cells using the RNeasy kit from Qiagen (Hilden, Germany). Reverse transcription was performed with the SuperscriptII kit using random hexamers (Gibco). The GM-CSF-receptor alpha chain cDNA was then amplified using the following primers:
5': N-GCRa-plusSS: TTCTCTGGATCCGCCACCATGCTTCTCCTGGTGACAAGCC and
3': C-flGCRa: ACCCTCCAATTGTCAGGTAATTTCCTTCACGGTC.
The PCR reaction yielded a product of ~1250bp which was digested with EcoRI and BamHl (New England BioLabs). The expression vector pcDNA3.1(+) (Invitrogen, Paisley, UK) was digested with the same enzymes. After purification of the digested vector and PCR product, the fragments were ligated and transformed by electroporation into E.coli DHlOB cells. Correct clones were identified after preparation of plasmid DNA and sequencing. Correct clones (pcDNA3.1(+)-GM-CSFRalpha) contained the full length human GM-CSF receptor alpha cDNA.
CHO-Kl cells were grown according to the provider's protocol (DSZM, Braunschweig, Germany; DSMZ No. ACC 110). For transfection cells were grown to 80% confluence in a 6- well plate and incubated with 5μg DNA of pcDNA3.1(+)-GM-CSFRalpha mixed with lOμl of the Lipofectamine 2000 reagent (Invitrogen). After 48h cells were fed with lmg/ml G418 (Gibco) and after another 24h medium was replaced with such containing 2mg/ml G418. After two weeks single cells were seeded into wells of a 96-well culture dish. Single clones were grown up and 5x105 cells of each clone were tested for GM- CSFR-alpha expression by FACS analysis using murine IgG MAB 1006 (Chemicon International, Temecula, CA) as primary antibody at a concentration of lμg/ml and (R-PE- AffiniPure (Fab')2 Goat-anti-mouse-IgG (Dianova) as secondary antibody at a 1 :200 dilution. Primary and secondary antibodies were incubated with the cells for Ih sequen- tially, while cells were washed in FACS buffer (PBS, 3%FCS) between these steps. Fluorescence of stained cells was quantified in the FL2 channel using a FACSCalibur system (Becton Dickinson).
Among the clones analyzed clone CHO-GMRa#l l showed the highest median fluorescent intensity. A median fluorescence value (MFL value) of 157 was determined for CHO-GMRa#l l (Fig. 6)
FACS analysis of GM-CSF binding to the GM-CSF receptor alpha expressed on CHO-
GMRa#l l :
Prior to adding to cells, antibodies at increasing concentrations (0.1 to 100 μg/ml) were co-incubated with biotinylated GM-CSF (0.5μg/ml) in FACS buffer (PBS/3%FBS/NaN30,05%) for 30min at RT.
All stainings were performed in round bottom 96- well culture plates (Nalge Nunc) with 1- 5 x 105 cells per well. 2xlOE5 CHO-GMRa#l l cells were taken up in 50μl of the anti- body/GM-CSF containing FACS buffer and incubated at 40C for Ih. Cells were then washed once with 150μl FACS buffer/well and taken up in lOOμl phycoerythrin-labeled streptavidin (BD Biosciences Pharmingen) which has been diluted 1 :400 in FACS buffer. After Ih incubation at 40C cells were washed twice with FACS buffer, resuspended in lOOμl of FACS buffer and binding of biotinylated GM-CSF was measured via FL2 fluorescence intensity of cells in FACScalibur (Becton Dickinson). IC50 values were deter- mined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit.
Fab antibodies MOR03682, MOR03684 and MOR03929 showed significant inhibition of GM-CSF binding to the cell surface expressed GM-CSF receptor alpha. Example 4: Affinity maturation of selected Fab by stepwise exchange of CDR cassettes
A. Generation of affinity maturation Fab libraries and pannings In order to increase the affinity and inhibitory activity of the anti-GM-CSF Fab fragments clones MOR03682, MOR03684 and MOR03929 were subjected to affinity maturation. In this regard, CDR regions were optimized by cassette mutagenesis using trinucleotide directed mutagenesis (VirnekSs et ah, 1994; Nagy et al., 2002). Sequence analysis revealed no sequence homology between the CDRs of the three parental clones analyzed. Table 2a and 2b provide the six CDR peptide sequences for the parental clones MOR03682, MOR03684 and MOR03929.
The following briefly describes the protocol used for Fab optimization. Fab fragments from expression vector pMORPH®X9Fab_FH were cloned into a phagemid vector (US 6,753,136). Then, two different strategies were applied to optimize the affinity and effi- cacy of the parental Fabs.
First, one phage antibody Fab library was generated where the L-CDR3 of each parental was replaced by a repertoire of individual lambda light chain CDR3 sequences. In a second library the H-CDR2 region was replaced by a repertoire of individual heavy chain CDR2 sequences. Affinity maturation libraries were generated by transforming the diversified clones into E. coli TOPlOF' (Invitrogen). Phages were prepared as described in Example IA. Both L- CDR3 libraries of MOR03684 and MOR03682 were pooled and both H-CDR2 libraries derived from MOR03684 and MOR03682 were pooled, while the L-CDR3 and H-CDR2 libraries derived from MOR03929 were kept separately during the selection procedure. Pannings were performed on biotinylated GM-CSF in solution for three rounds essentially as described in Example IB and applying more stringent selection conditions.
B. Electrochemiluminescene (BioVeris) based binding analysis for detection of improved GM-CSF binding Fab in lysates For the detection of GM-CSF binding Fab antibodies in E. coli lysates (BEL extracts), binding was analyzed in the BioVeris M-384 SERIES® Workstation (BioVeris Europe, Witney, Oxforfshire, UK) essentially as described in Example 2B. Fabs with the highest ECL values were purified and subjected to affinity measurement by solution equilibrium titration (SET; Haenel et al, 2005) and surface plasmon resonance (Biacore) (see Example 4D)
C. X-cloning of improved VL (L-CDR3) with improved VH (H-CDR2)
For a further improvement of affinity the independently optimized H-CDR2 and L-CDR3 from matured Fabs which were derived from the same parental clone were combined, because there was a high probability that this combination would lead to a further gain of affinity (Yang et al., 1995; Schier et al., 1996; Chen et al., 1999). This procedure, called X-cloning, was applied for binders that were derived from the parental clone MOR03929 as Fabs with improved affinities were identified from both the H-CDR2 and the L-CDR3 library. This was accomplished by transferring whole light chains (Xbal/Sphl fragment) from the L-CDR3 -optimized donor clone to the H-CDR2-optimized acceptor clone.
Table 3: X-cloning combinations
Figure imgf000049_0001
For the resulting 4 Fabs the VL and VH was sequenced to confirm transfer of the correct VL to the respective H-CDR2 improved vector backbone. Table 2a and 2b show the VH and VL protein sequences of all derivatives of MOR03929 and 3682, which are listed in table 3.
D. Determination of picomolar affinities using Solution Equilibrium Titration (SET) and surface plasmon resonance (Biacore)
For KD determination, monomer fractions (at least 90% monomer content, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) of Fab were used. Electrochemilu- minescence (ECL) based affinity determination in solution and data evaluation were basically performed as described by Haenel et al., 2005: A constant amount of Fab was equilibrated with different concentrations (serial 5" dilutions) of human GM-CSF (Leu- comax) in solution. Biotinylated human GM-CSF (R&D Systems) coupled to paramag- netic beads (M-280 Streptavidin, Dynal) and BV -tag™ (BioVeris Europe, Witney, Ox- forfshire, UK) labeled anti-human (Fab)'2 (Dianova) was added and incubated for 15 - 30 min. Subsequently, the concentration of unbound Fab was quantified via ECL detection using a M- SERIES® 384 analyzer (BioVeris Europe).
In accordance with Friguet et al., 1985, care was taken to avoid significant equilibrium shift to solid phase during detection.
Using the assay conditions described above affinities for the Fabs were determined, which are shown in table 4.
Additionally kinetic SPR analysis was performed on an Fl chip (Biacore, Sweden) which was coated with a density of ~ 100 RU recombinant human GM-CSF (Peprotech) in 10 mM Na-acetate pH 4.5 using standard EDC-NHS amine coupling chemistry. A respective amount of HSA was immobilized on the reference flow cell. PBS (136 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4 pH 7.4) + 0.005 % Tween 20 was used as running buffer. Fab was applied in concentration series of 6.3 - 200 nM at a flow rate of 20 μl/min. Association phase was set to 60 s and dissociation phase to 120 s (parental) or up to 600 s (affinity optimized). In order to monitor dissociation phase over a longer period, the following conditions, basically according to Drake et al., (2004) were used: Fab was applied in a single concentration of 200 nM; flow rate was set to 100 μl/min and dis- sociation phase to 6000 - 18.000 s. On the basis of the off-rates determined under these assay conditions affinities for the Fabs were estimated, which are shown in table 4. Table 4: Affinities of anti-hGM-CSF Fabs determined by Biacore and solution equilibrium titration (SET)
Biacore SET
Figure imgf000051_0001
3684 6420 16000
4251 70 7.4
3929 4260 2000
4302 174 63.5
4287 nd 17.9
4252 55 6
4290 122 11.1
4350 19 1.1
4354 21 2.8
4357 7 0.4
3682 nd 11406
4283 nd 113
4297 nd 49.2
4342 nd 4.9
E. Determination of affinities to rat GM-CSF using Solution Equilibrium Titration (SET)
Affinity determination to rat GM-CSF was done essentially as described in Example 4D using rat-GM-CSF (Peprotech) as analyte in solution instead of human GM-CSF. Affinities were calculated according to Haenel et al (2005). In this assay affinity of Fab MOR04357 to rat GM-CSF was determined to be KD = 1.0 nM. Example 5: Characterization of optimized anti-human GM-CSF Fabs that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha chain A. GM-CSF receptor alpha binding assay
The GM-CSF receptor binding assay was performed as described above (Example 3C) using 0.5μg/ml (35nM) of biotinylated GM-CSF. Maximal binding of GM-CSF to CHO- GMRa#l l cells (0% inhibition) was measured by incubating cells at a final GM-CSF concentration of 0.5μg/ml of biotinylated GM-CSF, without the addition of antibody. 100% inhibition of GM-CSF binding was measured by omitting GM-CSF from the assay. IC50 values were determined from the dose response curves obtained using GraphPad
10 Prism v3.03 software applying a non-linear regression curve fit.
Fabs with improved affinities, the parental Fabs and monoclonal reference IgGs were analyzed. Table 5 summarizes the IC50 values obtained in these assays. The % inhibition achieved at an antibody concentration of 5μg/ml is also given in table 5.
15 Table 5 : IC50 values of anti-hGM-CSF Fabs in receptor inhibition assay
MOR0# 4251 4357 4354 4350 4252 4287 4290 4302 3684 3929 Mab215 21C11
IC50 (nM) 53 26 26 24 26 25 27 24 >400 35 no fit* 9
% inhibition at 5μg/ml -100% -75% -75% -75% -75% -75% -75% -75% -25% -60% -50% -100% antibody
"no sigmoidal dose response curve could be fitted in this case
This assay qualitatively showed that the Fabs obtained from affinity maturation and X- cloning prevent GM-CSF from binding to the GM-CSF receptor alpha chain and therefore retained the blocking mechanism of their parental Fabs. The assay needed to be performed with a concentration of 35nM (0.5 μg/ml) biotinylated GM-CSF in order to obtain a significant signal in FACS. Therefore 17.5 nM Fab (or 8.75 nM IgG) is theoretically needed to block 50% of the GM-CSF, thus setting a limit for determination of IC50 values.
B. Inhibition of GM-CSF dependent proliferation of TF-I by anti-hGM-CSF Fabs using human GM-CSF
TF-I proliferation assay was performed as described in Example 3B. Fab with improved affinities and the parental Fabs as well as monoclonal reference IgGs were analyzed. IC50 values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 6 summarizes the ICs0 values obtained in these assays.
Table 6: IC50 values of anti-hGM-CSF Fabs and control IgGs in TF-I proliferation assay
Figure imgf000054_0001
In another set of experiments IC50 values in the TF-I proliferation assay were determined for the parental Fab MOR03682, its affinity matured derivatives MOR04283, MOR04297 and the x-cloned variant MOR04342. Table 7 summarizes the IC50 values obtained in these assays.
Table 7: IC50 values of anti-hGM-CSF Fabs in TF-I proliferation assay
Figure imgf000055_0001
These experiments demonstrated the large improvements achieved in ICs0 values after affinity maturation and X-cloning. For example, MOR04357, MOR04350, MOR04354 show >2000fold improved IC50 values compared to their parental MOR03929 and exceed the potency of BVD2-21C11 and Mab215
Example 6: Conversion of MOR04357 to human IgGl format
A. Gene optimization of Fab DNA sequences for expression in mammalian expression systems.
To optimize DNA of the VH and VL of MOR04357 for mammalian gene expression (e.g. changing codon usage, GC content, etc.) GeneOptimizer™ software from Geneart (Regens- burg, Germany ) was utilized to define such optimized VH and VL DNA sequences, which were gene synthesized at Geneart (Regensburg, Germany) and cloned into pPCR-Script vectors yielding 055906pPCR-Script and 055907pPCR-Script . SEQ ID NO: 48 shows the re- spective VH sequence, while SEQ ID NO: 57 shows the respective VL sequence. B. Cloning of Fab MOR04357 into human IgGl format and IgGl expression
In order to express full length immunoglobulin (Ig), variable domain fragments of the gene optimized heavy (VH) and light chains (VL) were subcloned from the pPCR-Script vectors (Example5a) into the the pMORPH®2_h_Ig vector series for human IgGl. Codon-optimized VH of MOR04357 was isolated from 055906pPCR-Script via NheVBlpl digestion and inserted into pMorph2_h_IgG If master vector cut with the same restriction enzymes. This vector already contained a human gamma 1 constant region. The resulting expression plasmid was termed pMorph2_h_IgGlf_MOR04357_co. Codon-optimized VL of MOR04357 was isolated from 055907pPCR-Script via NheVHpal digestion and inserted into pMorph2_h_Iglambda2 master vector cut with the same restriction enzymes. This vector already contained a human lambda constant region. The resulting expression plasmid was termed pM2_h_Iglambda2_MOR04357_co.
C. Transient Expression and Purification of Human IgG
Eukaryotic HKBI l cells were transfected with an equimolar amount of IgG heavy and light chain expression vector DNA. Cell culture supernatant was harvested from 3 to 7 days post transfection. After adjusting the pH of the supernatant to 8.0 and sterile filtration, the solution was subjected to standard protein A affinity chromatography (rProteinA FF or MabSelect SURE, GE Healthcare). Buffer exchange was performed to 1 x Dulbcecco's PBS (pH 7,2, Invitrogen) and samples were sterile filtered (0,2 μm). MOR04357 IgGl was dialysed against 1 x Dulbcecco's PBS (pH 6,5, Invitrogen). Purity of IgG was analysed under denaturing, reducing conditions in SDS-PAGE or by using Agilent BioAnalyzer and in native state by SE- HPLC.
D. Determination of picomolar affinities using Solution Equilibrium Titration (SET)
For KD determination, monomer fractions (at least 90% monomer content, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) of IgGl were used. Electrochemilumi- nescence (ECL) based affinity determination in solution and data evaluation were basically performed as described by Haenel et al., 2005 and as described in Example4B. The KD val- ues for MOR04357 IgGl against human recombinant GM-CSF was determined to be 1.1 pM.
E. Determination of affinities to rat GM-CSF using Solution Equilibrium Titration
(SET)
Affinity determination to rat GM-CSF was done essentially as described in Example 4D using rat-GM-CSF (Peprotech) as analyte in solution instead of human GM-CSF. Affinities were calculated according to Haenel et al (2005). The KD value for the MOR04357 IgGl against rat recombinant GM-CSF was determined to be 130 pM.
Example 7: Characterization of MOR04357 IgGl derived from optimized anti-human GM-CSF Fabs
A. Inhibition of GM-CSF dependent proliferation of TF-I by anti-hGM-CSF
IgGs using human and rhesus GM-CSF
TF-I proliferation assay was performed as described in Example 3B. MOR04357 was analyzed in IgGl format and as control monoclonal reference IgGs were analyzed. IC50 values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 8 summarizes the IC50 values obtained in these assays. Three different variants of GM-CSF were used in this assay: Firstly, recombinant human GM-CSF at a concentration of 0.25 ng/ml, produced in E. coli , secondly, culture supernatant from HEK293 which have been transiently transfected with pcDNA-huGM-CSF (see Example 3A), containing recombinant human GM-CSF and thirdly, culture supernatant from HEK293 cells which have been transiently transfected with pcDNA-macGM-CSF (see Example 3A), containing recombinant macaca mulatto (rhesus) GM-CSF. For TF-I proliferation assays the HEK293 culture supernatants were used as a source of the respective GM- CSF in such dilutions that TF-I cells showed a similar proliferation as compared to prolifera- tion given at the defined concentration of 0.25 ng/ml purified recombinant human GM-CSF produced in E. coli.
Table 8: IC50 values of MOR04357 IgG and control IgGs in TF-I proliferation assay IC50 (pM) human human macaca
GM-CSF GM-CSF GM-CSF
(E.coli) (HEK293) (HEK293)
MOR04357 IgGl 48 11 15
21C1 1 1668 144 128
Mab215 625 54 190
This experiment demonstrated the large improvements achieved in IC50 values after affinity maturation and X-cloning where preserved after conversion from Fab to IgGl format. IgGl MOR04357 shows >2000fold improved IC50 values compared to Fab MOR03929 and exceeds the potency of BVD2-21C11 and Mab215.
References:
Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, and Firestein GS. (1991). Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-I and tumor necrosis factor-alpha. J Immunol 146, 3365- 3371.
Babior, B. (2000). Phagocytes and oxidative stress. Am J Med 109, 33-44.
Bonfield,T.L., Kavuru.M.S., and Thomassen,M.J. (2002). Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 105, 342-350.
Bozinovski,S., JonesJ., Beavitt,S.J., Cook,A.D., Hamilton, J. A., and Anderson,G.P. (2003). Innate immune responses to lipopolysaccharide in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol Lung Cell MoI Physiol.
Broide,D.H. and Firestein,G.S. (1991). Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest 88, 1048-1053.
Broide,D.H., Paine,M.M., and Firestein,G.S. (1992). Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 90, 1414-1424.
Brown,C.B., Pihl,C.E., and Kaushansky,K. (1994). Mapping of human granulocyte- macrophage-colony-stimulating-factor domains interacting with the human granulocyte- macrophage-colony-stimulating-factor-receptor alpha-subunit. Eur J Biochem 225, 873-880. Burmester,G.R., Stuhlmuller.B-, Keyszer.G., and Kinne.R.W. (1997). Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 40, 5- 18.
Campbell,I.K., Bendele,A., Smith,D.A., and Hamilton,J.A. (1997). Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 56, 364-368.
Campbell,I.K., Rich,M.J., Bischof,R.J., Dunn,A.R., Grail,D., and HamiltonJ.A. (1998). Pro- tection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor- deficient mice. J Immunol 161, 3639-3644.
CarrieriJP.B., Provitera,V., De RosaJ., Tartaglia,G., Gorga,F., and Perella,O. (1998). Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple scle- rosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol. 20, 373-382.
CebonJ., Nicola,N.A., Ward,M., Gardner,L, Dempsey,P.J., Layton,J.E., Dϋhrsen,U., Bur- gess,A., Nice,E.C, and Morstyn.G. (1990). Granulocyte-macrophage stimulating factor from human lymphocytes. J Biol Chem 265, 4483-4491.
Chantry,D., Turner,M., Brennan,F., Kingsbury.A., and Feldmann,M. (1990). Granulocyte- macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine 2, 60-67.
Chen Y., Wiesmann C, Fuh G., Li B., Christinger H.W., McKay .P, de Vos A.M., Lowman H.B. (1999)
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity- matured Fab in complex with antigen.
J MoI Biol. 293, 865-81.
Cheng,S.S., LaiJ.J., Lukacs,N.W., and Kunkel,S.L. (2001). Granulocyte-macrophage colony stimulating factor up-regulates CCRl in human neutrophils. J Immunol 166, 1178-1184.
Clark,S.C. and Kamen,R. (1987). The human hematopoietic colony-stimulating factors. Science 236, 1229-1237.
Cook,A.D., Braine,E.L., Campbell,I.K., Rich,M.J., and Hamilton,J.A. (2001). Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony- stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Ar- thritis Res 3, 293-298.
de Groot,R.P., Coffer.P.J., and Koenderman,L. (1998). Regulation of prolifera- tion,differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 10, 619-628. de Vries,E.G., Willemse,P.H., Biesma,B., Stern,A.C, Limburg,P.C, and Vellenga,E. (1991). Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 338, 517-518.
Diederichs,K., Boone,T., and Karplus,P.A. (1991). Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. Science 254, 1779- 1782.
Drake A. W., Myszka D.G., Klakamp S.L. (2004)
Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem. 328, 35-43.
DranoffjG., Crawford, A.D., Sadelain,M., Ream,B., Rashid,A., Bronson,R.T., Dickersin,G.R., Bachurski.C.J., Mark,E.L., WhitsettJ.A., and (1994). Involvement of granulocyte- macrophage colony-stimulating factor in pulmonary homeostasis. Science 264, 713-716.
Friguet B., Chaffotte A..F, Djavadi-Ohaniance L., Goldberg M.E. (1985),
Measurements of the true affinity constant in solution of antigen-antibody complexes by en- zyme-linked immunosorbent assay. J Immunol Methods. 77,305-19.
Gasson,J.C, Baldwin,G.C, Sakamoto,K.M., and DiPersioJ.F. (1990a). The biology of human granulocyte-macrophage colony-stimulating factor (GM-CSF). Prog Clin Biol Res 352, 375- 384. Gasson,J.C, Fraser,J.K., and Nimer,S.D. (1990b). Human granulocyte-macrophage colony- stimulating factor (GM-CSF): regulation of expression. Prog Clin Biol Res 338, 27-41.
GassonJ.C, Kaufman,S.E., Weisbart,R.H., Tomonaga.M., and Golde,D.W. (1986). High- affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci U S A. 83, 669-673. Gearing,D.P., King,J.A., Gough,N.M., and Nicola,N.A. (1989). Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J. 12, 3667- 3676.
Gomez-Cambronero,J., Horn, J., Paul.C.C, and Baumann,M.A. (2003). Granulocyte- macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol 171, 6846-6855.
Haenel, C, Satzger, M., Delia Ducata, D., Ostendorp, R. and Brocks, B. (2005). Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration. Analytical Biochemistry, 339, 1, 182-184.
Hamilton,J.A. (1993). Rheumatoid arthritis: opposing actions of hemopoietic growth factors and slow acting anti-rheumatic drugs. Lancet 342, 536-539.
HamiltonJ.A. (2002). GM-CSF in inflammation and autoimmunity. Trends Immunol 23, 403- 408. Hart,P.H., Whitty,G.A., Piccoli,D.S., and Hamilton, J. A. (1988). Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-I activity. J Immunol 141, 1516-1521.
Haworth,C, Brennan,F.M., Chantry,D., Turner,M, Maini,R.N., and Feldmann,M. (1991). Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21, 2575-2579.
Hayashida,K., Kitamura,T., Gorman,D.M, Arai,K., Yokota,K., and Miyajima,A. (1990). Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A 87, 9655-9659.
Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, and Vellenga E (1989). Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony- stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthri- tis. Blood 74, 2769-2780.
Kastelein,R.A. and Shanafelt,A.B. (1993). GM-CSF receptor: interactions and activation. Oncogene S, 231-236.
Kaufman,S.E., DiPersioJ.F., and GassonJ.C. (1989). Effects of human GM-CSF on neutrophil degranulation in vitro. Exp Hematol 17, 800-804.
Kitamura,T., Sato,N., Arai,K., and Miyajima,A. (1991). Expression cloning of the human IL- 3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 66, 1165-1174.
Kitamura,T., Tanaka,N., Watanabe,J., Uchida, Kanegasaki,S., Yamada,Y., and Nakata,K. (1999). Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190, 875-880.
Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., Piao Y.F., Mi- yazono K., Urabe A., Takaku F. (1989).
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin J Cell Physiol. 140, 323-34.
Knappik,A., Ge5L., Honegger,A., Pack,P., Fischer,M., Wellnhofer,G., Hoess,A., Wolle,J., Pluckthun,A., and Virnekas,B. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleo- tides. J MoI Biol 296, 57-86.
KrebSjB., Rauchenberger,R., Reiffert,S., Rothe,C, Tesar,M., Thomassen,E., Cao,M., Dreier,T., Fischer,D., Hoss,A., Inge,L., Knappik,A., Marget,M., Pack,P., Meng,X.Q., Schier,R., Sohlemann,P., WinterJ., WoIIe5J., and Kretzschmar,T. (2001). High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods 254, 67- 84.
Lopez,A.F., Williamson,D.J., Gamble.J.R., Begley,C.G., Harlan.J.N., Klebanoff,SJ., WaI- tersdorph.A., Wong,G.5 Clark,S.C, and Vadas.M.A. (1986). Recombinant human granulo- cyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78, 1220-1228.
McQualter,J.L., Darwiche,R., Ewing,C, Onuki,M., Kay,T.W., Hamilton,J.A., Reid.H.H., and Bernard,C.C. (2001). Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194, 873-882.
Meager,A., Wadhwa,M., Bird,C, Dilger,P., Thorpe,R., Newsom-Davis,J., and Willcox,N. (1999). Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 97, 526-532.
Metcalf,D., Begley,C.G., Johnson,G.R., Nicola,N.A., Vadas,M.A., Lopez,A.F., William- son,DJ., Wong,G.G., CIark,S.C, and Wang,E.A. (1986). Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67, 37-45.
Mulherin,D., Fitzgerald,O., and Bresnihan,B- (1996). Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39, 1 15-124.
Nagy Z.A., Hubner B., Lohning C, Rauchenberger R., Reiffert S., Thomassen-Wolf E., Zahn S., Leyer S., Schier E.M., Zahradnik A., Brunner C, Lobenwein K., Rattel B., Stanglmaier M., Hallek M., Wing M., Anderson S., Dunn M., Kretzschmar T., Tesar M. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of ma- lignant lymphoid cells. Nat Med. 8, 801-7
Olver,I.N., Hercus,T., Lopez,A., Vadas,M., Somogyi,A.A., Doyle,I., Foster,D.J., Keefe,D., Taylor,A., Brown,M., To,L.B., CoIe5J., Rawling,T., Cambareri,B., Myers,M., Olszewski,N., Bastiras,S., Senn,C, Hey,A., Verma,M., and Wigley,P. (2002). A phase I study of the GM- CSF antagonist E21R. Cancer Chemother Pharmacol 50, 171-178. Plenz,G., Eschert,H., Beissert,S., Arps.V., Sindermann,J.R., Robenek,H., and Vδlker,W. (2003). Alterations in the vascular extracellular matrix of granulocyte-macrophage colony- stimulating factor (GM-CSF)-deficient mice. FASEB J. 17, 1451-1457.
Rapoport,A.P., Abboud,C.N., and DiPersio,J.F. (1992). Granulocyte-macrophage colony- stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev 6, 43-57.
Rauchenberger,R., Borges.E., Thomassen-Wolf, E., Rom,E., Adar,R., Yaniv,Y., Malka,M., Chumakov.I., Kotzer,S., Resnitzky.D., Knappik,A., Reiffert,S., PrasslerJ., Jury,K., WaId- herr,D., Bauer,S., Kretzschmar,T., Yayon,A., and Rothe,C. (2003). Human combinatorial Fab Library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem.
Santiago-Schwarz F, Anand P,L.S., and Carsons SE (2001). Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate ThI inflammatory-type responses. J Immunol 167, 1758-1768. Sato,N., Sakamaki,K., Terada,N., Arai,K., and Miyajima,A. (1993). Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 12, 4181-4189. Schier R., McCaIl A., Adams G..P, Marshall K. W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C, Marks J.D. (1996)
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J MoI Biol. 8, 263:551-67.
ShanafeltjA.B., Johnson,K.E., and Kastelein,R.A. (1991a). Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J Biol Chem 266, 13804-13810.
Shanafelt,A.B., Miyajima,A., Kitamura,T., and Kastelein,R.A. (1991b). The amino-terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors. EMBO J 10, 4105-4112.
Shibata,Y.s Berclaz,P.-Y., Chroneos,Z., Yoshida,H., and Trapnell,B.C. (2001). GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU. Immunity 75, 557-567.
Sisson,S.D. and Dinarello,C.A. (1988). Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte- macrophage colony-stimulating factor. Blood 72, 1368-1374.
Stanley,E., Lieschke,G.J., Grail,D., Metcalf,D., Hodgson,G., GallJ.A., Maher,D.W., Ce- bon,J., Sinickas,V., and Dunn.A.R. (1994). Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 91, 5592-5596.
Trapnell,B-C and Whitsett,J.A. (2002). GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 64, 775-802.
Uchida,K., Nakata,K., Trapnell,B.C, Terakawa,T., Hamano,E., Mikami,A., Matsushita,I., Seymour,J.F., Oh-Eda,M., IshigeJ., Eishi,Y., Kitamura,T., Yamada,Y., Hanaoka,K., and Keicho,N. (2004). High-affinity autoantibodies specifically eliminate granulocyte- macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103, 1089-1098.
Virnekϋs, B., Ge, L., Plϋckthun, A., Schneider, K.C., Wellnhofer, G. & Moroney, S.E., (1994). Nucleic Acids Research 22, 5600-5607. Xu,W.D., Firestein,G.S., Taetle,R., Kaushansky,K., and Zvaifler.N.J. (1989). Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83, 876-882.
Yamashita,N., Tashimo.H., Ishida,H., Kaneko.F., NakanoJ., Kato.H., Horiuchi,T., and Ohta,K. (2002). Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of GM-CSF. Cell Immunol 219, 92-97. Yang W.P., Green K., Pinz-Sweeney S., Briones A.T., Burton D.R., Barbas CF. 3rd. (1995). CDR walking mutagenesis for the affinity maturation of a potent human anti-HIY-l antibody into the picomolar range. J MoI Biol. 254, 392-403
Zhang.Y., McCluskey,K., FuJu5K., and Wahl,L.M. (1998). Differential regulation of monocyte matrix metalloproteinase and TIMP-I production by TNF-alpha, granulocyte- macrophage CSF, and IL-I beta through prostaglandin-dependent and -independent mechanisms. J Immunol 161, 3071-3076.

Claims

1. An isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x105 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM-CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about
2x105 CH0-GMRa#l 1 cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibody BVD2-21C11.
2. An isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2xlO5 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM-CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x105 CH0-GMRa#l 1 cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5μg/rnl; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibody MAB215.
3. An isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2xlO5 CHO-Kl cells by at least 50% under the following conditions: (a) the con- centration of said human GM-CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x105 CHO-GMRa#l l cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibodies MAB215 and BVD2-21C11.
4. An isolated human or humanized antibody or functional fragment thereof according to claim 1 , wherein said antibody or functional fragment thereof is cross-reactive with rat GM-CSF and/or rhesus GM-CSF .
5. An isolated human or humanized antibody or functional fragment thereof according to claim 2, wherein said antibody or functional fragment thereof is cross-reactive with rat GM-CSF and/or rhesus GM-CSF.
6. An isolated human or humanized antibody or functional fragment thereof according to claim 3, wherein said antibody or functional fragment thereof is cross-reactive with rat GM-CSF and/or rhesus GM-CSF.
7. An isolated antigen-binding region of an antibody or a functional antibody fragment that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x105 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM- CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x105 CHO-GMRa#l 1 cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5 μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibody BVD2-21C1 1.
8. An isolated antigen-binding region of an antibody or a functional antibody fragment that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x105 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM-
CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x105 CHO-GMRa#l 1 cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower IC50 value than reference antibody
MAB215.
9. An isolated antigen-binding region of an antibody or a functional antibody fragment that is specific for human GM-CSF, wherein said isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x105 CHO-Kl cells by at least 50% under the following conditions: (a) the concentration of said human GM- CSF receptor alpha chain expressed on said CHO-Kl cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2xlO5 CHO-GMRa#l 1 cells, and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5 μg/ml; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-I proliferation assay with an at least five-fold lower ICs0 value than reference antibodies B VD2-21C11 and MAB215.
10. An isolated antigen-binding region that is specific for human GM-CSF, which comprises an H-CDR3 region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
11. An isolated antigen-binding region according to claim 10, further comprising an H-CDR2 region depicted in SEQ ID NO: 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
12. An isolated antigen-binding region according to claim 11, further comprising an H-CDRl region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52.
13. An isolated antigen-binding region according to claim 12, which comprises a variable heavy chain depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or
52.
14. An isolated antigen-binding region that is specific for human GM-CSF, which comprises an L-CDR3 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
15. An isolated antigen-binding region according to claim 14, further comprising an L-CDR2 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
16. An isolated antigen-binding region according to claim 15, further comprising an L-CDRl region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
17. An isolated antigen-binding region according to claim 16, which comprises a variable light chain depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
18. An isolated antigen-binding region that is specific for human GM-CSF, which comprises a heavy chain amino acid sequence having at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 5 l or 52.
19. An isolated antigen-binding region that is specific for human GM-CSF, which comprises a light chain amino acid sequence having at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.
20. An isolated functional antibody fragment according to claim 1, which is a Fab or scFv antibody fragment.
21. An isolated human or humanized antibody according to claim 1 , which is an IgG.
22. A variable heavy chain of an isolated human or humanized antibody or a functional antibody fragment that is encoded by (i) a nucleic acid sequence comprising SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, or (ii) a nucleic acid sequences that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, wherein said antibody or functional fragment thereof is specific for human GM-CSF.
23. A variable light chain of an isolated human or humanized antibody or a functional antibody fragment that is encoded by (i) a nucleic acid sequence comprising SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57, or (ii) a nucleic acid sequences that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57, wherein said antibody or functional fragment thereof is specific for human GM-CSF.
24. An isolated nucleic acid sequence that encodes an antigen-binding region of a human or humanized antibody or a functional antibody fragment according to any one of claims 7 to 9.
25. An isolated nucleic acid sequence according to claim 24, which comprises (i) SEQ ID NO: 2, 6, 8, 9, 10, 47 or 48 or (ii) a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 2, 6, 8, 9, 10, 47 or 48.
26. An isolated nucleic acid sequence according to claim 24, which comprises (i) SEQ ID NO: 22, 26, 28, 29, 30, 56 or 57 or (ii) a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 22, 26, 28, 29, 30, 56 or 57.
27. An isolated nucleic acid sequence that encodes an antigen-binding region of a human or humanized antibody or a functional antibody fragment, comprising (i) SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, or (ii) a nucleic acid sequences that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 1 , 2, 3, 4, 5,
6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, wherein said antibody or functional fragment thereof is specific for human GM-CSF.
28. An isolated nucleic acid sequence that encodes an antigen-binding region of a human or humanized antibody or a functional antibody fragment, comprising SEQ ID NO: 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57 or (ii) a nucleic acid sequences that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57 wherein said antibody or functional fragment thereof is specific for human GM-CSF.
29. A vector comprising a nucleic acid sequence according to any one of claims 24-28.
30. An isolated cell comprising a vector according to claim 29.
31. An isolated cell according to claim 30, wherein said cell is bacterial.
32. An isolated cell according to claim 30, wherein said cell is eukaryotic.
33. A pharmaceutical composition comprising a human or humanized antibody or functional fragment according to any one of claims 1 to 6, and a pharmaceutically acceptable carrier or excipient therefor.
34. A method of treating a disorder or condition associated with the undesired presence of GM-CSF, comprising the step of administering to a subject in need thereof an effective amount of the pharmaceutical composition according to claim 33. - 10 -
35. A method according to claim 34, wherein said disorder or condition is an inflammatory disease.
36. A method according to claim 35, wherein said inflammatory disease is taken from the list of rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis and shock.
37. A human antibody according to any one of claims 1 to 6, wherein the human antibody is a synthetic human antibody.
38. An isolated antigen-binding region according to claim 18 or 19, wherein said sequence identity is at least 80 percent.
PCT/EP2006/004696 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor WO2006122797A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
US11/914,599 US7867495B2 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies and uses therefor
KR1020077029189A KR101308087B1 (en) 2005-05-18 2006-05-17 Anti-GM-CSF Antibodies and Uses Therefor
JP2008511635A JP5295759B2 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibody and use thereof
AU2006249062A AU2006249062B2 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies and uses therefor
SI200631880T SI1888643T1 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
PL06742970T PL1888643T3 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
MEP-2015-5A ME02059B (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
CN2006800249817A CN101218255B (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses thereof
EP06742970.4A EP1888643B1 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
NZ564027A NZ564027A (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies and uses therefor
EP19180152.1A EP3620171B1 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
CA2608498A CA2608498C (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
RS20150018A RS53743B1 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
DK06742970.4T DK1888643T3 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies as well as their uses
BRPI0610796A BRPI0610796B8 (en) 2005-05-18 2006-05-17 isolated human or humanized antibody, or a fab or scfv fragment thereof, nucleic acid sequence, vector, and use of an antibody
ES06742970.4T ES2527428T3 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies and uses thereof
IL187375A IL187375A (en) 2005-05-18 2007-11-14 Anti-gm-csf antibodies, pharmaceutical compositions comprising them and uses thereof
NO20076437A NO344992B1 (en) 2005-05-18 2007-12-13 Anti-GM-CSF antibodies and uses for these
HK08109862.8A HK1114620A1 (en) 2005-05-18 2008-09-05 Anti-gm-csf antibodies and uses therefor
US12/923,363 US9751939B2 (en) 2005-05-18 2010-09-16 Anti-GM-CSF antibodies
HRP20150023TT HRP20150023T1 (en) 2005-05-18 2015-01-09 Anti-gm-csf antibodies and uses therefor
US15/386,152 US10377820B2 (en) 2005-05-18 2016-12-21 Methods of treatment using anti-GM-CSF antibodies
US16/442,779 US11028165B2 (en) 2005-05-18 2019-06-17 Nucleic acid encoding anti-GM-CSF antibodies
US17/314,198 US20210347879A1 (en) 2005-05-18 2021-05-07 Anti-gm-csf antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18
US60/682,009 2005-05-18

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/914,599 A-371-Of-International US7867495B2 (en) 2005-05-18 2006-05-17 Anti-GM-CSF antibodies and uses therefor
US12/923,363 Continuation US9751939B2 (en) 2005-05-18 2010-09-16 Anti-GM-CSF antibodies
US12/923,363 Division US9751939B2 (en) 2005-05-18 2010-09-16 Anti-GM-CSF antibodies

Publications (3)

Publication Number Publication Date
WO2006122797A2 true WO2006122797A2 (en) 2006-11-23
WO2006122797A3 WO2006122797A3 (en) 2007-02-15
WO2006122797B1 WO2006122797B1 (en) 2007-04-19

Family

ID=37114333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004696 WO2006122797A2 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor

Country Status (26)

Country Link
US (5) US7867495B2 (en)
EP (4) EP3620171B1 (en)
JP (2) JP5295759B2 (en)
KR (1) KR101308087B1 (en)
CN (2) CN103087190B (en)
AR (1) AR053608A1 (en)
AU (1) AU2006249062B2 (en)
BR (1) BRPI0610796B8 (en)
CA (1) CA2608498C (en)
DK (2) DK1888643T3 (en)
ES (2) ES2918209T3 (en)
HK (1) HK1114620A1 (en)
HR (2) HRP20220755T3 (en)
HU (1) HUE058876T2 (en)
IL (1) IL187375A (en)
LT (1) LT3620171T (en)
ME (1) ME02059B (en)
NO (1) NO344992B1 (en)
NZ (1) NZ564027A (en)
PL (2) PL1888643T3 (en)
PT (2) PT3620171T (en)
RS (2) RS53743B1 (en)
RU (1) RU2447085C2 (en)
SI (2) SI3620171T1 (en)
TW (1) TWI477512B (en)
WO (1) WO2006122797A2 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092939A3 (en) * 2006-02-08 2008-03-27 Morphotek Inc Antigenic gm-csf peptides and antibodies to gm-csf
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
WO2009038760A2 (en) * 2007-09-18 2009-03-26 Amgen Inc. Human gm-csf antigen binding proteins
WO2009064399A1 (en) * 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
EP2101780A2 (en) 2006-11-21 2009-09-23 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2160407A1 (en) * 2007-05-23 2010-03-10 Crc For Asthma And Airways Ltd Neutralizing antibodies
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
EP2217626A1 (en) * 2007-11-12 2010-08-18 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
EP2280732A2 (en) * 2008-04-28 2011-02-09 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
WO2010124163A3 (en) * 2009-04-23 2011-03-03 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US7935795B2 (en) 2005-10-26 2011-05-03 Evec Inc. Human monoclonal antibody binding to hGM-CSF and its antigen binding portion
US20120003234A1 (en) * 2008-12-22 2012-01-05 The University Of Melbourne Osteoarthritis treatment
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2634196A1 (en) 2007-11-26 2013-09-04 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor
WO2013161814A1 (en) 2012-04-23 2013-10-31 ジーンフロンティア株式会社 Anti-human cd69 antibody, and use thereof for medical purposes
WO2014044768A1 (en) 2012-09-20 2014-03-27 Morphosys Ag Treatment for rheumatoid arthritis
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
WO2014068026A1 (en) 2012-10-31 2014-05-08 Amgen Research (Munich) Gmbh Liquid formulation comprising gm-csf neutralizing compound
WO2014073292A1 (en) 2012-11-09 2014-05-15 ジーンフロンティア株式会社 Anti-adam28 antibody for treating cancer
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US9067993B2 (en) 2005-04-18 2015-06-30 Amgen Research (Munich) Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
WO2015169742A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
US10647779B2 (en) 2009-04-29 2020-05-12 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor
WO2020097321A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2020247521A1 (en) 2019-06-03 2020-12-10 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2447085C2 (en) 2005-05-18 2012-04-10 МорфоСис АГ Anti-gm-csf antibodies and using them
CN102171247A (en) * 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-alpha antagonist multi-target binding proteins
BR112013033944A2 (en) * 2011-07-06 2017-12-19 Morphosys Ag synergistic combination
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
JP6437913B2 (en) 2012-08-17 2018-12-12 モルフォシス・アーゲー Complex-specific antibodies and antibody fragments and uses thereof
KR20210021153A (en) * 2012-09-20 2021-02-24 모르포시스 아게 Treatment for rheumatoid arthritis
JP6490419B2 (en) * 2014-12-24 2019-03-27 学校法人関西医科大学 Regulatory T cell differentiation inducer
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
CN107614527A (en) 2015-03-06 2018-01-19 基因先端领域株式会社 Anti-human film type ADAM28 antibody
JP7256116B2 (en) * 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド ANTI-GM-CSF ANTIBODY AND USES THEREOF
CN107840886B (en) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 GM-CSF antibodies and uses thereof
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499161A2 (en) 1991-02-11 1992-08-19 Bristol-Myers Squibb Company GM-CSF inhibiting antibodies
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO2003068920A2 (en) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5747032A (en) * 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
AUPP525198A0 (en) * 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
JP4555089B2 (en) 2002-11-15 2010-09-29 モーフオテク・インコーポレーテツド Method for producing high production amount of antibody from hybridoma created by in vitro immunization
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
RU2447085C2 (en) * 2005-05-18 2012-04-10 МорфоСис АГ Anti-gm-csf antibodies and using them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499161A2 (en) 1991-02-11 1992-08-19 Bristol-Myers Squibb Company GM-CSF inhibiting antibodies
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6300064B1 (en) 1995-08-18 2001-10-09 Morphosys Ag Protein/(poly)peptide libraries
WO2003068920A2 (en) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1995, JOHN WILEY AND SONS
"OLIGONUCLEOTIDE SYNTHESIS", 1984, IRL PRESS
"Remington's Pharmaceutical Sciences", 1980
"REMINGTON'S PHARMACEUTICAL SCIENCES", 1990, MACK PUB. CO.
"REMINGTON'S PHARMACEUTICAL SCIENCES", 1990, MACK PUB. CO., pages: 484 - 528
GROSSMAN, H. B., UROL. CLIN. NORTH AMER, vol. 13, 1986, pages 465 - 474
KHAW, B. A. ET AL., SCIENCE, vol. 209, 1980, pages 295 - 297
KHORANA ET AL., J. MOL. BIOL., vol. 72, 1971, pages 209 - 217
KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57
KREBS ET AL., J. IMMUNOL. METHODS., vol. 254, 2001, pages 67
SAMBROOK, J.; FRITSCH, E. F.; MANIATIS, T.: "Molecular Cloning: A laboratory manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
UNGER, E. C. ET AL., INVEST. RADIOL., vol. 20, 1985, pages 693 - 700

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138297B2 (en) 2005-04-18 2018-11-27 Amgen Research (Munich) Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
US9067993B2 (en) 2005-04-18 2015-06-30 Amgen Research (Munich) Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
US7935795B2 (en) 2005-10-26 2011-05-03 Evec Inc. Human monoclonal antibody binding to hGM-CSF and its antigen binding portion
US7741450B2 (en) 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
US8318168B2 (en) 2006-02-08 2012-11-27 Morphotek, Inc. Antigenic GM-CSF peptides and antibodies to GM-CSF
US10023632B2 (en) 2006-02-08 2018-07-17 Morphotek, Inc. Antigenic GM-CSF peptides and antibodies to GM-CSF
EP3181585A3 (en) * 2006-02-08 2017-08-30 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US8623364B2 (en) 2006-02-08 2014-01-07 Morphotek, Inc. Antigenic GM-CSF peptides and antibodies to GM-CSF
US9422367B2 (en) 2006-02-08 2016-08-23 Morphotek, Inc. Antigenic GM-CSF peptides and antibodies to GM-CSF
WO2007092939A3 (en) * 2006-02-08 2008-03-27 Morphotek Inc Antigenic gm-csf peptides and antibodies to gm-csf
WO2008063898A3 (en) * 2006-11-08 2008-10-30 Kalobios Pharmaceuticals Inc Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
EP2101780A2 (en) 2006-11-21 2009-09-23 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2160407A1 (en) * 2007-05-23 2010-03-10 Crc For Asthma And Airways Ltd Neutralizing antibodies
JP2010527939A (en) * 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド Neutralizing antibody
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
CN101861336A (en) * 2007-09-18 2010-10-13 安姆根有限公司 Human GM-CSF antigen binding proteins
WO2009038760A2 (en) * 2007-09-18 2009-03-26 Amgen Inc. Human gm-csf antigen binding proteins
JP2010538676A (en) * 2007-09-18 2010-12-16 アムジェン インコーポレイテッド Human GM-CSF antigen binding protein
US8268311B2 (en) 2007-09-18 2012-09-18 Amgen Inc. Human GM-CSF antigen binding proteins
US8481704B2 (en) 2007-09-18 2013-07-09 Amgen Inc. Nucleic acid molecule encoding human GM-CSF antigen binding proteins
EP2236519A1 (en) * 2007-09-18 2010-10-06 Amgen, Inc Human GM-CSF antigen binding proteins
AU2008302747B2 (en) * 2007-09-18 2012-02-02 Amgen Inc. Human GM-CSF antigen binding proteins
WO2009038760A3 (en) * 2007-09-18 2009-08-20 Amgen Inc Human gm-csf antigen binding proteins
EP2217626A4 (en) * 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
EP2217626A1 (en) * 2007-11-12 2010-08-18 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
EP2535353A1 (en) 2007-11-13 2012-12-19 Evec Inc. Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
WO2009064399A1 (en) * 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
RU2517596C2 (en) * 2007-11-13 2014-05-27 Эвек Инк. MONOCLONAL ANTIBODIES BINDING WITH hGM-CSF AND COMPOSITIONS FOR MEDICINAL PURPOSES, CONTAINING THEREOF
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
EP2559706A1 (en) * 2007-11-13 2013-02-20 Evec Inc. Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
EP2634196A1 (en) 2007-11-26 2013-09-04 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
EP3449941A1 (en) * 2008-04-28 2019-03-06 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
EP2280732A2 (en) * 2008-04-28 2011-02-09 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US8168183B2 (en) 2008-04-28 2012-05-01 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
EP2280732A4 (en) * 2008-04-28 2012-11-14 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
CN102037016B (en) * 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 Antibodies to granulocyte-macrophage colony-stimulating factor
JP2011518886A (en) * 2008-04-28 2011-06-30 カロバイオス ファーマシューティカルズ インコーポレイティッド Antibody to granulocyte-macrophage colony stimulating factor
CN102037016A (en) * 2008-04-28 2011-04-27 卡罗拜奥斯制药公司 Antibodies to granulocyte-macrophage colony-stimulating factor
US9017674B2 (en) 2008-04-28 2015-04-28 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009142738A3 (en) * 2008-05-21 2010-03-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP3381471A1 (en) * 2008-12-22 2018-10-03 The University of Melbourne Pain treatment
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
US9834599B2 (en) 2008-12-22 2017-12-05 The University Of Melbourne Pain treatment
US9352034B2 (en) 2008-12-22 2016-05-31 The University Of Melbourne Methods of treating pain using an antibody specific for GM-CSF
RU2712273C2 (en) * 2008-12-22 2020-01-28 Де Юниверсити Оф Мельбурн Osteoarthritis treatment
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
RU2712166C2 (en) * 2008-12-22 2020-01-24 Де Юниверсити Оф Мельбурн Pain treatment
RU2630969C2 (en) * 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Pain treatment
EP2387418B1 (en) * 2008-12-22 2018-06-13 The University of Melbourne Pain treatment
US8475796B2 (en) 2008-12-22 2013-07-02 University Of Melbourne Method of treating pain using an antagonist of GM-CSF
US20120003234A1 (en) * 2008-12-22 2012-01-05 The University Of Melbourne Osteoarthritis treatment
WO2010124163A3 (en) * 2009-04-23 2011-03-03 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
CN102459340A (en) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US10647779B2 (en) 2009-04-29 2020-05-12 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor
US10781263B2 (en) 2009-04-29 2020-09-22 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
AU2010244525B2 (en) * 2009-05-05 2013-03-28 Morphosys Ag Treatment for multiple sclerosis
CN102439039A (en) * 2009-05-05 2012-05-02 莫佛塞斯公司 Treatment of multiple sclerosis
RU2539034C2 (en) * 2009-05-05 2015-01-10 МорфоСис АГ Method of treating multiple sclerosis
WO2013161814A1 (en) 2012-04-23 2013-10-31 ジーンフロンティア株式会社 Anti-human cd69 antibody, and use thereof for medical purposes
WO2014044768A1 (en) 2012-09-20 2014-03-27 Morphosys Ag Treatment for rheumatoid arthritis
EP3345923A1 (en) 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
AU2016250388B2 (en) * 2012-09-20 2018-07-19 Morphosys Ag Treatment for rheumatoid arthritis
EP3916013A1 (en) 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
US10913792B2 (en) 2012-09-20 2021-02-09 Morphosys Ag Treatment for rheumatoid arthritis
EA031489B1 (en) * 2012-09-20 2019-01-31 МорфоСис АГ Method of treating rheumatoid arthritis
WO2014068026A1 (en) 2012-10-31 2014-05-08 Amgen Research (Munich) Gmbh Liquid formulation comprising gm-csf neutralizing compound
US9919051B2 (en) 2012-10-31 2018-03-20 Amgen Research (Munich) Gmbh Liquid formulation comprising GM-CSF neutralizing compound
EP3744344A1 (en) 2012-10-31 2020-12-02 Amgen Research (Munich) GmbH Liquid formulation comprising gm-csf neutralizing compound
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US10758621B2 (en) 2012-10-31 2020-09-01 Amgen Research (Munich) Gmbh Liquid formulation comprising GM-CSF neutralizing compound
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
EP3473718A1 (en) 2012-11-09 2019-04-24 GeneFrontier Corporation Anti-adam28 antibody for treating cancer
WO2014073292A1 (en) 2012-11-09 2014-05-15 ジーンフロンティア株式会社 Anti-adam28 antibody for treating cancer
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US11795216B2 (en) 2013-08-30 2023-10-24 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2015169742A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
WO2020097321A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
WO2020247521A1 (en) 2019-06-03 2020-12-10 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US11325979B2 (en) 2020-03-15 2022-05-10 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with GM-CSF antagonists
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Also Published As

Publication number Publication date
AU2006249062A1 (en) 2006-11-23
NO344992B1 (en) 2020-08-17
IL187375A (en) 2012-06-28
EP3150221A1 (en) 2017-04-05
EP2468773A3 (en) 2012-09-19
US9751939B2 (en) 2017-09-05
DK1888643T3 (en) 2015-01-05
LT3620171T (en) 2022-06-10
ES2527428T3 (en) 2015-01-23
HRP20220755T3 (en) 2022-09-02
SI1888643T1 (en) 2015-03-31
HRP20150023T1 (en) 2015-02-27
TW200716674A (en) 2007-05-01
EP1888643B1 (en) 2014-10-29
BRPI0610796B8 (en) 2021-05-25
BRPI0610796B1 (en) 2020-01-21
ME02059B (en) 2015-05-20
PT3620171T (en) 2022-06-30
EP2468773A2 (en) 2012-06-27
KR101308087B1 (en) 2013-10-16
AR053608A1 (en) 2007-05-09
RS63382B1 (en) 2022-08-31
RU2007147870A (en) 2009-06-27
WO2006122797A3 (en) 2007-02-15
CA2608498A1 (en) 2006-11-23
RS53743B1 (en) 2015-06-30
SI3620171T1 (en) 2022-09-30
KR20080015008A (en) 2008-02-15
EP1888643A2 (en) 2008-02-20
JP2013116912A (en) 2013-06-13
US10377820B2 (en) 2019-08-13
US20170218061A1 (en) 2017-08-03
US20090053213A1 (en) 2009-02-26
NO20076437L (en) 2007-12-13
US11028165B2 (en) 2021-06-08
CA2608498C (en) 2017-04-04
CN103087190A (en) 2013-05-08
CN101218255B (en) 2013-01-09
JP5769744B2 (en) 2015-08-26
HK1114620A1 (en) 2008-11-07
US7867495B2 (en) 2011-01-11
RU2447085C2 (en) 2012-04-10
ES2918209T3 (en) 2022-07-14
US20110045000A1 (en) 2011-02-24
CN103087190B (en) 2016-08-03
PL1888643T3 (en) 2015-04-30
WO2006122797B1 (en) 2007-04-19
IL187375A0 (en) 2008-02-09
JP2008545632A (en) 2008-12-18
PT1888643E (en) 2015-01-14
AU2006249062B2 (en) 2012-12-20
BRPI0610796A2 (en) 2010-11-09
PL3620171T3 (en) 2022-08-08
CN101218255A (en) 2008-07-09
TWI477512B (en) 2015-03-21
HUE058876T2 (en) 2022-09-28
EP3620171A1 (en) 2020-03-11
JP5295759B2 (en) 2013-09-18
US20200024340A1 (en) 2020-01-23
US20210347879A1 (en) 2021-11-11
NZ564027A (en) 2011-06-30
EP3620171B1 (en) 2022-04-20
DK3620171T3 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
US11028165B2 (en) Nucleic acid encoding anti-GM-CSF antibodies
AU2010202813B2 (en) Anti- MCP-1 antibodies, compositions, methods and uses
WO2009006359A2 (en) Anti- mcp-1 antibodies, compositions, methods and uses
AU2013201224A1 (en) Anti-GM-CSF antibodies and uses therefor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2608498

Country of ref document: CA

Ref document number: 187375

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11914599

Country of ref document: US

Ref document number: MX/a/2007/014521

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008511635

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 8984/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006249062

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 564027

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020077029189

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006742970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007147870

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680024981.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2006249062

Country of ref document: AU

Date of ref document: 20060517

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006249062

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006742970

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0610796

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071119

WWE Wipo information: entry into national phase

Ref document number: P-2015/0018

Country of ref document: RS